MIRA INFORM REPORT

Report Date :

18.12.2013

IDENTIFICATION DETAILS

Name :	EVONIK INDUSTRIES AG
Registered Office :	Rellinghauser, Strasse 1-11, Essen, 45128
Country :	Germany
Financials (as on) :	31.12.2012
Date of Incorporation :	12.09.2007
Com. Reg. No.:	HRB19474
Legal Form :	Public Subsidiary
Line of Business :	Subject is engaged in manufacture of plastic tableware, kitchenware and toilet articles; and manufacture of diverse plastic products (plastic headgear, insulating fittings, parts of lighting fittings, office or school supplies, articles of apparel, fittings for furniture, statuettes, transmission and conveyor belts)
No. of Employees :	33,531

RATING & COMMENTS

MIRA’s Rating :

Ba

RATING		STATUS	PROPOSED CREDIT LINE
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory

Status :	Good
Payment Behaviour :	No complaints
Litigation :	Clear

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

ECGC Country Risk Classification List – March, 31^st, 2013

Country Name	Previous Rating (31.12.2012)	Current Rating (31.03.2013)
Germany	A1	A1

Risk Category	ECGC Classification
Insignificant	A1
Low	A2
Moderate	B1
High	B2
Very High	C1
Restricted	C2
Off-credit	D

GERMANY - ECONOMIC OVERVIEW

The German economy - the fifth largest economy in the world in PPP terms and Europe's largest - is a leading exporter of machinery, vehicles, chemicals, and household equipment and benefits from a highly skilled labor force. Like its Western European neighbors, Germany faces significant demographic challenges to sustained long-term growth. Low fertility rates and declining net immigration are increasing pressure on the country's social welfare system and necessitate structural reforms. Reforms launched by the government of Chancellor Gerhard SCHROEDER (1998-2005), deemed necessary to address chronically high unemployment and low average growth, contributed to strong growth in 2006 and 2007 and falling unemployment. These advances, as well as a government subsidized, reduced working hour scheme, help explain the relatively modest increase in unemployment during the 2008-09 recession - the deepest since World War II - and its decrease to 6.5% in 2012. GDP contracted 5.1% in 2009 but grew by 4.2% in 2010, and 3.0% in 2011, before dipping to 0.7% in 2012 - a reflection of low investment spending due to crisis-induced uncertainty and the decreased demand for German exports from recession-stricken periphery countries. Stimulus and stabilization efforts initiated in 2008 and 2009 and tax cuts introduced in Chancellor Angela MERKEL's second term increased Germany's total budget deficit - including federal, state, and municipal - to 4.1% in 2010, but slower spending and higher tax revenues reduced the deficit to 0.8% in 2011. In 2012 Germany reached a budget surplus of 0.1%. A constitutional amendment approved in 2009 limits the federal government to structural deficits of no more than 0.35% of GDP per annum as of 2016 though the target was already reached in 2012. By 2014, the federal government wants to balance its budget. Following the March 2011 Fukushima nuclear disaster, Chancellor Angela Merkel announced in May 2011 that eight of the country's 17 nuclear reactors would be shut down immediately and the remaining plants would close by 2022. Germany hopes to replace nuclear power with renewable energy. Before the shutdown of the eight reactors, Germany relied on nuclear power for 23% of its electricity generating capacity and 46% of its base-load electricity production.

Source : CIA

Company name & address

EVONIK INDUSTRIES AG

Rellinghauser
Strasse 1-11
Essen, 45128
Germany
Tel:	49-20-117701
Fax:	49-20-117734
corporate.evonik.com

Employees:

33,531

Company Type:

Public Subsidiary

Corporate Family:

158 Companies

Ultimate Parent:

RAG-Stiftung

Traded:

XETRA:

EVK

Incorporation Date:

12-Sep-2007

Auditor:

PricewaterhouseCoopers AG

Financials in:	As Reported (mil) As Reported (000) USD (mil) USD (000) GBP (mil) GBP (000) EUR (mil) EUR (000)
Fiscal Year End:	31-Dec-2012
Reporting Currency:	Euro
Annual Sales:	17,512.7 ^1
Net Income:	1,495.7
Total Assets:	22,688.3 ^2
Market Value:	17,340.4
	(22-Nov-2013)

Business Description

Evonik Industries AG (Evonik) is a Germany-based company engaged in the specialty chemicals sector. It has five business segments: Consumer Health and Nutrition, Resource Efficiency, Specialty Materials, Services and Real Estate. The Consumer Health and Nutrition produces specialty chemicals, principally for applications in consumer goods, animal nutrition and pharmaceutical sectors. The Resource Efficiency segment provides solutions for environment-friendly and energy-efficient products. The Specialty Materials produces polymer materials and their preproducts, and additives. The Services segment mainly provides services for Evonik’s chemicals segments and Corporate Center, but also serves third parties. The Real Estate segment comprises Evonik's portfolio of residential real estate and a 50% stake in THS. As of December 31, 2011, the Company had a number of subsidiaries in Germany, Austria, the United Kingdom, Thailand, France, the United States, Brazil and Hong Kong, among others. For the nine months ended 30 September 2013, Evonik Industries AG revenues decreased 4% to EUR9.74B. Net income before extraordinary items decreased 28% to EUR588M. Revenues reflect Specialty Materials segment decrease of 55% to EUR1.13B, Consumer, Health and Nutrition segment decrease of 50% to EUR1.06B, Rest of Europe segment decrease of 53% to EUR1B, Germany segment decrease of 54% to EUR747M.

Industry

Industry	Synthetic Chemical Manufacturing
ANZSIC 2006:	1821 - Synthetic Resin and Synthetic Rubber Manufacturing
ISIC Rev 4:	2013 - Manufacture of plastics and synthetic rubber in primary forms
NACE Rev 2:	2016 - Manufacture of plastics in primary forms
NAICS 2012:	325211 - Plastics Material and Resin Manufacturing
UK SIC 2007:	2016 - Manufacture of plastics in primary forms
US SIC 1987:	2821 - Plastics Materials, Synthetic Resins, and Nonvulcanizable Elastomers

Key Executives

Name	Title
Klaus Engel	Chairman of the Executive Board, Chief Executive Officer
Ute Wolf	Chief Financial Officer
Jason Fox	Director, Oil and Gas Group
Thomas Wessel	Member of the Executive Board, Director of Human Resources
Oliver Luckenbach	Head of Investor Relations

Significant Developments

Topic	#*	Most Recent Headline	Date
Officer Changes	1	Evonik Industries AG to Appoint New CFO	29-May-2013
Equity Investments	1	Temasek Holdings To Buy Stake In Evonik Industries AG-Reuters	10-Mar-2013

* number of significant developments within the last 12 months

News

Title	Date
Prize awarded to new membrane technology from Evonik; German Federal Environment Ministry and BDI acknowledge SEPURAN Green with the German Innovation Prize for Climate and the Environment ENP Newswire (670 Words)	5-Dec-2013
Evonik starts innovation campaign; Patrik Wohlhauser, Executive Board Member: 'We want to increase the value of our innovation pipeline even further.'; Evonik laboratories demonstrate feasibility of producing specialty chemicals from syngas using biotech production ENP Newswire (1007 Words)	4-Dec-2013
Evonik Industries: More clout for strategic research; Creavis to operate in new structure from 2014 onward; Sustainability as an innovation driver ENP Newswire (593 Words)	4-Dec-2013
Evonik: Bacteria like the taste of syngas ENP Newswire (775 Words)	4-Dec-2013
WIPO PUBLISHES PATENT OF EVONIK INDUSTRIES AG TITLED AS "DIRECT CURING OF REACTIVE RESINS BY MEANS OF PLASMA INDUCTION" Plus Patent News (519 Words)	2-Dec-2013
Findings from P. Morfeld et al in Silicosis Reported Health & Medicine Week (334 Words)	20-Nov-2013

Financial Summary

As of 30-Sep-2013

Key Ratios	Company	Industry
Current Ratio (MRQ)	1.86	2.18
Quick Ratio (MRQ)	1.44	1.35
Debt to Equity (MRQ)	0.43	0.82
Sales 5 Year Growth	-2.31	6.26
Net Profit Margin (TTM) %	5.97	10.56
Return on Assets (TTM) %	4.50	8.26
Return on Equity (TTM) %	13.07	22.07

Traded: XETRA: EVK

As of 22-Nov-2013

   Financials in: EUR

Recent Price	27.62	EPS	2.47
52 Week High	33.20	Price/Sales	0.94
52 Week Low	23.97	Price/Earnings	14.73
Avg. Volume (mil)	0.19	Price/Book	2.40
Market Value (mil)	12,870.92

	Price % Change	Rel S&P 500%
4 Week	1.04%	-1.52%
13 Week	-3.12%	-11.55%

Registered No.(Other): HRB19474

Parent Registered No.(UK): DEU

1 - Profit & Loss Item Exchange Rate: USD 1 = EUR 0.7782366

2 - Balance Sheet Item Exchange Rate: USD 1 = EUR 0.7566

Corporate Overview

Location
Rellinghauser
Strasse 1-11
Essen, 45128
Germany

Tel:	49-20-117701
Fax:	49-20-117734

corporate.evonik.com

Quote Symbol - Exchange
EVK - XETRA
Sales EUR(mil):	13,629.0
Assets EUR(mil):	17,166.0
Employees:	33,531
Fiscal Year End:	31-Dec-2012

Industry:	Chemicals - Plastics and Rubber

Incorporation Date:	12-Sep-2007
Company Type:	Public Subsidiary
Quoted Status:	Quoted
Previous Name:	RAG Beteiligungs AG
Registered No.():	HRB19474
Parent Registered No.(UK):	DEU

Chairman of the Executive Board, Chief Executive Officer:	Klaus Engel

Industry Codes

ANZSIC 2006 Codes:
1821	-	Synthetic Resin and Synthetic Rubber Manufacturing
3323	-	Industrial and Agricultural Chemical Product Wholesaling
1841	-	Human Pharmaceutical and Medicinal Product Manufacturing
1813	-	Basic Inorganic Chemical Manufacturing

ISIC Rev 4 Codes:
2013	-	Manufacture of plastics and synthetic rubber in primary forms
2100	-	Manufacture of pharmaceuticals, medicinal chemical and botanical products
2011	-	Manufacture of basic chemicals
4669	-	Wholesale of waste and scrap and other products n.e.c.

NACE Rev 2 Codes:
2016	-	Manufacture of plastics in primary forms
2110	-	Manufacture of basic pharmaceutical products
4675	-	Wholesale of chemical products
2013	-	Manufacture of other inorganic basic chemicals

NAICS 2012 Codes:
325211	-	Plastics Material and Resin Manufacturing
325411	-	Medicinal and Botanical Manufacturing
325180	-	Other Basic Inorganic Chemical Manufacturing
424690	-	Other Chemical and Allied Products Merchant Wholesalers

US SIC 1987:
2821	-	Plastics Materials, Synthetic Resins, and Nonvulcanizable Elastomers
5169	-	Chemicals and Allied Products, Not Elsewhere Classified
2833	-	Medicinal Chemicals and Botanical Products
2819	-	Industrial Inorganic Chemicals, Not Elsewhere Classified

UK SIC 2007:
2016	-	Manufacture of plastics in primary forms
2110	-	Manufacture of basic pharmaceutical products
4675	-	Wholesale of chemical products
2013	-	Manufacture of other inorganic basic chemicals

Business Description

Evonik Industries AG (Evonik) is a Germany-based company engaged in the specialty chemicals sector. It has five business segments: Consumer Health and Nutrition, Resource Efficiency, Specialty Materials, Services and Real Estate. The Consumer Health and Nutrition produces specialty chemicals, principally for applications in consumer goods, animal nutrition and pharmaceutical sectors. The Resource Efficiency segment provides solutions for environment-friendly and energy-efficient products. The Specialty Materials produces polymer materials and their preproducts, and additives. The Services segment mainly provides services for Evonik’s chemicals segments and Corporate Center, but also serves third parties. The Real Estate segment comprises Evonik's portfolio of residential real estate and a 50% stake in THS. As of December 31, 2011, the Company had a number of subsidiaries in Germany, Austria, the United Kingdom, Thailand, France, the United States, Brazil and Hong Kong, among others. For the nine months ended 30 September 2013, Evonik Industries AG revenues decreased 4% to EUR9.74B. Net income before extraordinary items decreased 28% to EUR588M. Revenues reflect Specialty Materials segment decrease of 55% to EUR1.13B, Consumer, Health and Nutrition segment decrease of 50% to EUR1.06B, Rest of Europe segment decrease of 53% to EUR1B, Germany segment decrease of 54% to EUR747M.

More Business Descriptions

Chemicals, Energy and Real Estate Business Areas

Holding Company; Chemical Products, Energy & Real Estate

Evonik Industries AG is primarily engaged in manufacture of plastic tableware, kitchenware and toilet articles; and manufacture of diverse plastic products (plastic headgear, insulating fittings, parts of lighting fittings, office or school supplies, articles of apparel, fittings for furniture, statuettes, transmission and conveyor belts)

Plastics materials or resins

Evonik Industries AG (Evonik) carries out the manufacture and sale of wide range of specialty chemicals. The company specializes in the production of electricity from coal and renewable energy sources. It is also involved in the business of coal power, renewable energies, trading and real estate. Evonik is a subsidiary of RAG-Stiftung. The company's business operations are classified into five segments, namely, Consumer, Health and Nutrition; Resource Efficiency; Specialty Materials; Services; and Real Estate. The company's Consumer, Health & Nutrition (CHN) segment produces specialty chemicals, which find applications in consumer goods, animal nutrition and pharmaceutical markets. It comprises the Consumer Specialties and Health & Nutrition business units. The consumer specialties division markets chemicals to the consumer goods industry for use in cleaning agents, personal care sector and hygiene products. The Health and Nutrition division carries out the manufacture and sale of essential amino acids for animal nutrition, active ingredients and catalysts. For the fiscal year ended December 2012, the company reported revenue of €4,204m from the CHN segment, reflecting an increase of 3% over revenue in 2011. The segment accounted for 31.34% of the company’s total revenue in 2012. The Resource Efficiency segment provides solutions for environment-friendly and energy-efficient products. It comprises the Inorganic Materials and Coatings and Additives Business Units. The Inorganic Materials division carries out the design of inorganic particles. Its products cater to the rubber and tire industry, producers of polycrystalline silicon and the coatings, printing of polycrystalline silicon and coatings and printing. Coatings and Additives unit produces functional polymers and high-quality monomer specialties for the adhesives, paints and coatings, and sealants industries. For the fiscal year ended December 2012, the company reported revenue of €3,131m from the Resource Efficiency segment, reflecting a decrease of 22.6% over revenue in 2011. The segment accounted for 23.34% of the company’s total revenue in 2012. Evonik's Specialty Materials produces polymer materials and intermediates for plastic and rubber industries. It comprises the Performance Polymers and Advanced Intermediates Business Units. The Performance Polymers segment manufactures high-performance materials for the automotive, aviation, electronics and photovoltaic’s markets. For the fiscal year ended December 2012, the company reported revenue of €4,843m from the Specialty Materials segment, reflecting a decrease of 0.8% over revenue in 2011. The segment accounted for 36.1% of the company’s total revenue in 2012. The Services segment provides site services and Evonik business services. It provides services for Evonik’s chemicals segments, corporate center and third parties. Evonik Business Services provides standardized administrative services such as IT, human resources, accounting and legal services. For the fiscal year ended December 2012, the company reported revenue of €999m from the Services segment, reflecting an increase of 4.9% over revenue in 2011. The segment accounted for 7.45% of the company’s total revenue in 2012. The company's Real Estate segment provides rental services to private households. For the fiscal year December ended 2012, the company reported revenue of €239m from the Real Estate segment, reflecting a decrease of 42% over revenue in 2011. The segment accounted for 1.78% of the company’s total revenue in 2012. Evonik's research and development activities are determined by the needs of the market. The company's efforts are aimed at maintaining and extending the technology leadership possessed in many areas of power plant engineering and in specialty chemicals. It has over 26,000 patents and pending patents and more than 7,700 trademarks. For the fiscal year December 2012, the company invested a total of €393m, for its research and development activities. Geographically, the company operates in six regions, namely Asia, North America, Germany, Central and South America, Other European countries and Middle East, Africa. For the fiscal year ended December 2012, Other European countries accounted for 31% of the company's total revenue, followed by Germany with 25%, Asia with 18%, North America with 18%, Central and South America with 6% and Middle East, Africa with 2% revenue. The company's key subsidiaries include Evonik Degussa GmbH, Evonik Degussa Antwerpen N.V., Evonik Degussa Canada, Inc., Evonik Degussa India Pvt. Ltd., Evonik Degussa Corporation and Evonik Degussa Chile S.A. In June 2013, Evonik and Dober Chemical Corp. launched two detergents specifically developed for cleaning coating equipment after processing pharmaceutical formulations based on EUDRAGIT RL/RS and EUDRAGIT NE/NM. In the same month, Evonik launched a new generation of PVC plasticizers under the ELATUR product brand. In the same period, the company’s Comfort & Insulation Business Line inaugurated a new Technical Service Center in Singapore. The launched its tenth project house, The Composites Project House, in Marl, with a branch in Darmstadt. Evonik opened a new innovation center for products for the cosmetics industry at its Goldschmidtstrabe site in Essen. In May 2013, Evonik's Business Line Comfort & Insulation launched its new website for polyurethane (PU) additives. In the same month, Evonik launched its Composites Project House in spring 2013. During the same period, EDF Luminus built a new wind turbine at Evonik's site in Antwerp. Evonik Industries and OPX Biotechnologies, Inc. entered into an agreement to jointly develop certain bio-based specialty chemicals. In April 2013, Evonik Corporation extended its contract with Georgia-based distribution company Lintech International LLC to expand distribution of its Coatings & Adhesive Resins Business Line product, DEGALAN, to customers on the West Coast. In March 2013, Evonik Birmingham Laboratories site received Current Good Manufacturing Practices (cGMP) certification from the Medicines and Healthcare Products Regulatory Agency (MHRA). In the same month, Evonik opened a new production facility for silane-modified polymers in Essen.In February 2013, the company’s subsidiary CyPlus GmbH signed joint venture agreement with Grupo Idesa S.A de C.V., a Mexico based company for the construction of a sodium cyanide plant in Coatzacoalcos, Mexico. In January 2013, the company signed letter of intent with Petronas to jointly develop production facilities related to hydrogen peroxide, C4 co-monomer and oxo-products within PETRONAS’ Refinery & Petrochemical Integrated Development (RAPID) project in Pengerang, Johor. During the same month, Evonik signed memorandum of understanding with Government of Rostov Region to start Biolys plant in Volgodonsk through the joint venture OOO DonBioTech. In January 2013, the company invested in the Cleantech Fund III of Emerald Technology Ventures.

Evonik Industries AG (Evonik) is a specialty chemical manufacturing company. It operates as a subsidiary of RAG-Stiftung. The company is also involved in the business of coal power, renewable energies, trading and real estate. The company specializes in the production of electricity from coal and renewable energy sources. Evonik focuses on engineering and consulting expertise in the design, building and operation of power plants. The company's business operations are classified into five segments, namely, Consumer, Health & Nutrition; Resource Efficiency; Specialty Materials; Services; and Real Estate. Geographically, the company operates in more than 100 countries across Africa, South America, North America, Australia, Europe and Asia. Evonik is headquartered in Essen, Germany.

Evonik Industries established under this name in September 2007 is still a young group. Click on the link on the right to enter our history portal. Here you can learn about the origins of Evonik Industries. Also available are a large number of articles on the history of the sites outstanding technical in-novations and the people who left their mark on the history of the company. And of course we can help you delve even deeper into the history of Evonik. Just send us an e-mail using one of the addresses on the Contacts page. For more than 50 years Corporate Archives has been providing historical information on all matters pertaining to the history of the present company and its predecessors. As a valuable memory store it preserves the expertise of many generations of employees and makes it available to those working at Evonik today. In this way Corporate Archives actively contrib-utes to creating value for the company.

Chemicals - Diversified (Major)

Financial Data

Financials in:	EUR(mil)
Revenue:	13,629.0
Net Income:	1,164.0
Assets:	17,166.0
Long Term Debt:	1,464.0
Total Liabilities:	11,808.0
Working Capital:	2.5
Date of Financial Data:	31-Dec-2012

1 Year Growth

-12.4%

5.5%

1.3%

Market Data

Quote Symbol:	EVK
Exchange:	XETRA
Currency:	EUR
Stock Price:	27.6
Stock Price Date:	11-22-2013
52 Week Price Change %:	0.0
Market Value (mil):	12,870,920.0
SEDOL:	B5ZQ9D3
ISIN:	DE000EVNK013
Equity and Dept Distribution:
09/2007, Company name changed from RAG AG. Company has withdrawn its IPO. 07/2009, Company Re-activated.

Subsidiaries

Company	Percentage Owned	Country
Evonik Degussa Hong Kong Ltd.	100%	HONG KONG SAR
BHS Projektentwicklungs-GmbH & Co. KG	100%	GERMANY
STEAG Power Saar GmbH		GERMANY
Evonik Degussa Mexico S.A. de C.V.	100%	MEXICO
Evonik Pension Scheme Trustee Limited	100%	UK
Evonik Degussa Peroxide Ltd.	100%	NEW ZEALAND
Evonik Goldschmidt GmbH	100%	GERMANY
Evonik Oxeno GmbH	100%	GERMANY
Evonik Röhm GmbH	100%	GERMANY
Evonik Gorapur GmbH	100%	GERMANY
Evonik Stockhausen GmbH	100%	GERMANY
Evonik Fernwärme GmbH	100%	GERMANY
Evonik Trading GmbH	100%	GERMANY
Evonik Immobilien GmbH	100%	GERMANY
Evonik Wohnen GmbH	100%	GERMANY
Evonik Power Minerals GmbH	100%	GERMANY
STEAG-Raffinerei-Kraftwerk Sachsen-Anhalt GmbH	100%	GERMANY
Evonik Grubengas-Holding NRW GmbH	100%	GERMANY
Evonik New Energies GmbH	100%	GERMANY
Evonik Peroxygens GmbH	100%	GERMANY
Evonik Persalze GmbH	100%	GERMANY
Evonik Projekt-Beteiligung Verwaltungs-GmbH	100%	GERMANY
Evonik Risk and Insurance Services GmbH	100%	GERMANY
Evonik RohMax Additives GmbH	100%	GERMANY
Evonik Walsum 10 Kraftwerksbeteiligungsgesellschaft mbH	100%	GERMANY
Goldschmidt SKW Surfactants GmbH	100%	GERMANY
HD Ceracat GmbH	100%	GERMANY
Heinrich Schäfermeyer GmbH	100%	GERMANY
Industriepark Wolfgang GmbH	100%	GERMANY
Infracor Lager- und Speditions-GmbH	100%	GERMANY
Mönch-Kunststofftechnik GmbH	100%	GERMANY
Evonik Degussa (SEA) Pte. Ltd.	100%	SINGAPORE
Evonik Degussa (Shanghai) Co. Ltd.	100%	PEOPLE'S REPUBLIC OF CHINA
Evonik Degussa Taiwan Ltd.	100%	TAIWAN
Evonik Finance B.V.	100%	NETHERLANDS
Inspec Fine Chemicals Ltd	100%	UK
Inspec Invesco	100%	UK
Evonik Energy Services GmbH	100%	GERMANY
Evonik Cyro LLC	100%	USA
Evonik Amalgamation Ltd	100%	UK
Evonik Degussa (China) Co Ltd	100%	PEOPLE'S REPUBLIC OF CHINA
Evonik Degussa Brasil Ltda	100%	BRAZIL
Evonik Degussa Canada Inc	100%	CANADA
HVG Grünflächenmanagement GmbH		Germany
RÃœTGERS GmbH		Germany
Evonik Degussa GmbH		Germany
RBV Verwaltungs-GmbH		Germany
Evonik Risk and Insurance Services GmbH		Germany
RAG Verkauf GmbH		Germany
RHZ Handwerks-Zentrum GmbH		Germany
Vivawest GmbH		Germany
Evonik Services GmbH		Germany
Evonik Projekt-Beteiligung Verwaltungs-GmbH		Germany
Evonik Projekt-Beteiligungs-GmbH & Co. KG		Germany
Colortrend BM
Evonik Degussa (SEA) Pte. Ltd.
Asian Bleaching Earth Company Ltd	100%	THAILAND
Biomass Power Plant Ridham Limited	100%	UK
Evonik Degussa France Groupe S.A.S.	100%	FRANCE
BioKraft Karstädt GmbH	100%	GERMANY
Biomasse-Heizkraftwerk Ilmenau GmbH	100%	GERMANY
CyPlus GmbH	100%	GERMANY
Evonik Degussa Immobilien GmbH & Co. KG	100%	GERMANY
Evonik Goldschmidt Rewo GmbH	100%	GERMANY
Evonik TEGO Chemie GmbH	100%	GERMANY
OPUS Personaldienstleistungen GmbH	100%	GERMANY
R & B Industrieanlagenverwertung GmbH	100%	GERMANY
RHZ Handwerks-Zentrum GmbH	100%	GERMANY
WSA GmbH	100%	GERMANY
Colortrend Australia Pty. Ltd	100%	AUSTRALIA
AQura GmbH	100%	GERMANY
Asikos Strahlmittel GmbH	100%	GERMANY
ASTA Medica GmbH	100%	GERMANY
BHS Liegenschaften GmbH & Co. KG	100%	GERMANY
Advanced Polymer Technologies Europe GmbH	100%	GERMANY
Evonik Litarion GmbH	100%	GERMANY
Infracor GmbH	100%	GERMANY
Evonik Stockhausen LLC	100%	USA
Laporte Chemicals Ltd.	100%	UK
Laporte Industries Ltd.	100%	UK
Laporte Materials (Barrow) Ltd	100%	UK
Laporte Properties Limited	100%	UK
Peter Spence & Sons Limited	100%	UK
BHS Liegenschaften Verwaltungs-GmbH	100%	GERMANY
Cosmoferm B.V.	100%	NETHERLANDS
Degussa International Inc.	100%	USA
Degussa Re S.A.	100%	LUXEMBOURG
Evonik Aerosil France S.A.R.L.	100%	FRANCE
Evonik Australia Pty Ltd	100%	AUSTRALIA
Evonik Carbogal S.A.	100%	PORTUGAL
Power Minerals UK Holdings Limited	100%	UK
R + J Garroway Limited	100%	UK
Evonik Fermas s.r.o.	100%	SLOVAKIA
Evonik Degussa GmbH	100%	GERMANY
Evonik Degussa Corporation	100%	USA
Evonik Degussa Japan Co Ltd	100%	JAPAN
Evonik Degussa UK Holdings Ltd	100%	UK
Evonik Fibres GmbH	100%	AUSTRIA
Evonik RohMax USA Inc	100%	USA
Evonik Speciality Organics Ltd	100%	UK
NIPPON AEROSIL Co Ltd	100%	JAPAN
Iskenderun Enerji Ãœretim ve Ticaret Anonim Sirketi	51%	TURKEY
Elektrocieplownia Zdunska Wola Sp. z o.o.	100%	POLAND
Lünener Wohnungs- und Siedlungsgesellschaft mbH	100%	GERMANY
Rhein Lippe Wohnen GmbH	100%	GERMANY
Siedlung Niederrhein GmbH	100%	GERMANY
Walsum Immobilien GmbH	100%	GERMANY
Wohnbau Auguste Victoria GmbH	100%	GERMANY
Wohnbau Westfalen GmbH	100%	GERMANY
Wohnungsbaugesellschaft mbH "Glückauf"	100%	GERMANY
Aachener Bergmannssiedlungsgesellschaft mbH	100%	GERMANY
Evonik Chempower GmbH	100%	GERMANY
Evonik Degussa Ibérica S.A.	100%	SPAIN
Evonik Degussa India Pvt. Ltd.	100%	INDIA
Evonik Degussa International AG	100%	SWITZERLAND
Evonik Degussa Italia S.p.A.	100%	ITALY
Evonik Degussa Peroxid GmbH	100%	AUSTRIA
BK-Wolfgang-Wärme GmbH	100%	GERMANY

Shareholders

Major Shareholders

RAG Stiftung (74.99%); CVC Capital Partners (25.01%)

Key Corporate Relationships

Auditor:	PricewaterhouseCoopers AG
Bank:	Westdeutsche Landesbank Girozentrale
Auditor:	PricewaterhouseCoopers AG PricewaterhouseCoopers AG

Strategic Initiatives

Key Organizational Changes

In December 2011, the company entered into an agreement with SurModics, Inc. for the acquisition of its Pharmaceuticals business. During the same month, the company acquired the Kemira’s hydrogen peroxide facility in Maitland, Ontario, Canada. Through this acquisition, the company plans to increase its hydrogen peroxide production capacity in North America by 44,000 metric tons per annum. In May 2011, the company also signed an agreement for the acquisition of Hanse chemie Group. In March 2011, the company acquired RESOMER business from Boehringer Ingelheim.

During the same month, the company acquired the Kemira’s hydrogen peroxide facility in Maitland, Ontario, Canada. Through this acquisition, the company plans to increase its hydrogen peroxide production capacity in North America by 44,000 metric tons per annum. In May 2011, the company also signed an agreement for the acquisition of Hanse chemie Group. In March 2011, the company acquired RESOMER business from Boehringer Ingelheim. Evonik has more than 300 partnerships with universities around the world.

Partnerships

As you can see from this report, that opens up a wide range of new prospects. “Evonik 2016� is a major buttress for the successful future of the Group. We launched this corporate program in spring 2012 with a clear target: We want to mobilize our growth forces, raise efficiency further and ensure that leadership and collaboration in our company are shaped by trust and clear objectives. In short, our goal is a healthy balance of efficiency, values and growth. More than €6 billion has been earmarked for our ambitious investment program between 2012 and 2016, with €2 billion of this allocated to our home market in Germany and the same amount for the Asia-Pacific region.

Within the industry, industrial paints are expected to be the major segment as a result of rising infrastructure and industrial construction spending across the world. The industrial coatings market value is projected to be around 55 billion by 2020. Therefore, Evonik could gain from its coating and additive product line, which used in construction n and industrial sectors.Strategic InitiativesAs part of its business strategy, the company establishes and nourishes collaboration and agreements with other companies to enhance the scope of its business operations and bring non-dilutive capital into the company. In February 2013, the company’s subsidiary CyPlus GmbH signed joint venture agreement with Grupo Idesa S.A de C.V., a Mexico based company for the construction of a sodium cyanide plant in Coatzacoalcos, Mexico. In January 2013, the company signed letter of intent with Petronas to jointly develop production facilities related to hydrogen peroxide, C4 co-monomer and oxo-products within PETRONAS’ Refinery & Petrochemical Integrated Development (RAPID) project in Pengerang, Johor.

In February 2013, the company’s subsidiary CyPlus GmbH signed joint venture agreement with Grupo Idesa S.A de C.V., a Mexico based company for the construction of a sodium cyanide plant in Coatzacoalcos, Mexico. In January 2013, the company signed letter of intent with Petronas to jointly develop production facilities related to hydrogen peroxide, C4 co-monomer and oxo-products within PETRONAS’ Refinery & Petrochemical Integrated Development (RAPID) project in Pengerang, Johor. In December 2011, the company entered into an agreement with SurModics, Inc. for the acquisition of its Pharmaceuticals business. During the same month, the company acquired the Kemira’s hydrogen peroxide facility in Maitland, Ontario, Canada. Through this acquisition, the company plans to increase its hydrogen peroxide production capacity in North America by 44,000 metric tons per annum.

Resource Management

The LoI was signed in Kuala Lumpur on January 16, 2013. Petronas was represented by its COO and executive vice president of Downstream Business, Datuk Wan Zulkiflee Wan Ariffin, while Evonik was represented by its member of the executive board, Dr Dahai Yu. Dr Dahai Yu, said, "The entire project is set to mark another milestone in our growth strategy in the Asian market. This is why we’re seeking for a strong long-term strategic partner like Petronas." The partnership is expected to strengthen Petronas’s position as a key downstream petrochemical player in the region. 

Strengths/Weaknesses (SWOT)

	Helpful to achieving the objective	Harmful to achieving the objective
Internal Origin (attributes of the organization)	Strengths · Extensive Focus on Research and Development · Business Operations · Global Footprint	Weaknesses · Operational Constraints
External Origin (attributes of the environment)	Opportunities · Growth Opportunities in Emerging Markets · Growing Paint and Coatings Industry · Strategic Initiatives · Expansion Initiatives	Threats · Highly Competitive Market · Changes in Regulatory Environment · Foreign Currency Fluctuations

Overview

Evonik is one of the leading industrial groups in the world. It holds a key position in the specialty chemicals market. Evonik’s research and development activities involve approximately 2,500 people at 35 sites around the world that enables it to innovate and be a front-runner. However, operational constraints are a serious issue of concern. Nevertheless, the company has growth opportunities through growing demand for paints and coatings and its strategic expansion initiatives. However, increasing competition and changing regulations could also have a negative impact on the financial health of the company.

Strengths

Extensive Focus on Research and Development

The company is principally involved in research and development activities to attain new heights in business operations. Evonik’s research and development work in the chemical business area involves approximately 2,500 people at 35 sites around the world. During the fiscal year December 2012, the company invested around €393m in R&D activities, an increase of 8% over €365m in 2011. Evonik’s chemicals research focuses on the development of successful and established products and also at building new high-tech activities outside the company’s established business portfolio. Its current portfolio of patents and pending patents include more than 26,000, and it has more than 7,700 registered and pending trademarks. Such, strong research and development focus and broad patent portfolio enables the company to offer innovative products and solutions and maintain a competitive edge over its competitors.

Business Operations

Evonik is one of the leading industrial groups with operations around the world. It holds key market position in specialty chemicals area. The company is one of the global leaders in with chemical production facilities in 24 countries. Its business operations are grouped in five business segments, namely, Consumer, Health and Nutrition; Resource Efficiency; Specialty Materials; Services; and Real Estate. The company's Consumer, Health & Nutrition (CHN) segment manufactures specialty chemicals, which find applications in consumer goods, animal nutrition and pharmaceutical markets. The CHN segment comprises the Consumer Specialties and Health & Nutrition business units. The Resource Efficiency segment offers solutions for environment-friendly and energy-efficient products. It consists of Additives, and Inorganic Materials and Coatings Business Units. Its Specialty Materials segment produces polymer materials and their preproducts, and additives. The segment comprises the Performance Polymers and Advanced Intermediates Business Units. The services segment provides site services and Evonik business services. Under the Real Estate business segment, the company is engages in modernization, demolition and new construction activities. It involves in sale and rental of residential units, principally to private households. In January 2012, Evonik and THS merged the management of real estate properties in a newly formed joint venture, Vivawest Wohnen. Such business operations enable the company to have diverse revenue streams as well as help to identify its competitive advantage.

Global Footprint

Widespread geographical presence has enabled the company to cater to diverse industries worldwide. The company has broad global presence in Africa, Europe, Asia, North America, Australia and South America. Its global presence enables to make optimum use of arising growth opportunities as well as insulates the company from regulatory driven changes in individual national marketsFor the fiscal year ended December 2012, Other European countries accounted for 31% of the company's total revenue, followed by Germany with 25%, Asia with 18%, North America with 18%, Central and South America with 6% and Middle East, Africa with 2% revenue. The company’s global presence provides huge market potential for its products and services. It enables the company to expand its offerings and secure new contracts, acquisitions and joint ventures, which will generate additional revenues and thus will contribute to its growth. Further, global presence also reduces the impact of market volatility and provides economic stability to the company.

Weaknesses

Operational Constraints

Operational risk may occur due to capital investments, damage of property, raw material procurement and loss of reputation. The company’s operational facilities are decentralized and are managed through a network of geographically dispersed management personnel. Any disruption, unanticipated expense or operational failure related to this process could negatively impact the company’s facilities operations. In March 2012, a fire accident occurred at the CDT plant located in Marl Chemicals Park. The CDT plant offers cyclododecatriene, which serves as a material in plastics manufacturing. As a result of fire accident, the company incurred property damages as well as lost two employees. It also adversely affected the business of VESTAMID, VESTAMELT, VESTOSINT, and VESTENAMER product ranges. Such fire accidents and operational failure could affect the operational and financial performance e of the company.

Opportunities

Growth Opportunities in Emerging Markets

Through Coatings & Additives business, the company serves coatings, printing inks, and the adhesive and sealing compounds industries across the world. It offers product such as colorants, crosslinkers coating and adhesive resins, coating additives and oil additives. Paints and coating industry is witnessing substantial growth as a result of growing infrastructure industry. According to industry estimates, the worldwide demand for paint and coatings is expected to increase 5.4 % annually through 2015 to 45.5 million metric tons, with a total value of approximately $140 billion. The Asia Pacific is estimated to be the key market for consumer of paints and coatings. Within the industry, industrial paints are expected to be the major segment as a result of rising infrastructure and industrial construction spending across the world. The industrial coatings market value is projected to be around 55 billion by 2020. Therefore, Evonik could gain from its coating and additive product line, which used in construction n and industrial sectors.

Growing Paint and Coatings Industry

Through Coatings & Additives business, the company serves coatings, printing inks, and the adhesive and sealing compounds industries across the world. It offers product such as colorants, crosslinkers coating and adhesive resins, coating additives and oil additives. Paints and coating industry is witnessing substantial growth as a result of growing infrastructure industry. According to industry estimates, the worldwide demand for paint and coatings is expected to increase 5.4 % annually through 2015 to 45.5 million metric tons, with a total value of approximately $140 billion. The Asia Pacific is estimated to be the key market for consumer of paints and coatings. Within the industry, industrial paints are expected to be the major segment as a result of rising infrastructure and industrial construction spending across the world. The industrial coatings market value is projected to be around 55 billion by 2020. Therefore, Evonik could gain from its coating and additive product line, which used in construction n and industrial sectors.

Strategic Initiatives

As part of its business strategy, the company establishes and nourishes collaboration and agreements with other companies to enhance the scope of its business operations and bring non-dilutive capital into the company. In February 2013, the company’s subsidiary CyPlus GmbH signed joint venture agreement with Grupo Idesa S.A de C.V., a Mexico based company for the construction of a sodium cyanide plant in Coatzacoalcos, Mexico. In January 2013, the company signed letter of intent with Petronas to jointly develop production facilities related to hydrogen peroxide, C4 co-monomer and oxo-products within PETRONAS’ Refinery & Petrochemical Integrated Development (RAPID) project in Pengerang, Johor. In December 2011, the company entered into an agreement with SurModics, Inc. for the acquisition of its Pharmaceuticals business. During the same month, the company acquired the Kemira’s hydrogen peroxide facility in Maitland, Ontario, Canada. Through this acquisition, the company plans to increase its hydrogen peroxide production capacity in North America by 44,000 metric tons per annum. In May 2011, the company also signed an agreement for the acquisition of Hanse chemie Group. In March 2011, the company acquired RESOMER business from Boehringer Ingelheim. Evonik has more than 300 partnerships with universities around the world. Apart from acquisitions in its core business, the company also divested its loss making businesses. In April 2012, the sold its global colorants business to Arsenal Capital Partners. In August 2011, the company sold its subsidiary, namely, Evonik Lynchem Co., Ltd to Dalian Kionge Group Co., Ltd. It also divested its carbon black business and sold to Kinove German Bidco GmbH. Such initiatives will strengthen the company’s competitive market position as well as enhance its global presence.

Expansion Initiatives

The company focuses on product and capacity expansion activity for tapping new markets and customers. In June 2013, the company opened a new innovation center for the cosmetics industry at its Goldschmidtstrabe site in Essen. The innovation center and its developments will further reinforce its position in the growing global market for cosmetic products. In May 2013, Evonik started construction of production plant in Brazil. The plant is scheduled to be completed by 2015 and will support the silica market which is expected to grow at a rate of 30% between 2010 and 2014. In January 2013, the company expanding its market position in C4-based products and investing in the expansion of its production facilities. The company’s 1-butene capacity in Marl Chemical Park will be expanded by 75,000 tons; production of butadiene will be expanded by 100,000 tons in Antwerp, Belgium; and MTBE capacity in Marl and Antwerp will be expanded 150,000 tons. During the same month, STOKO Professional Skin Care, the Europe’s leading manufacturers of skin protection launched new red series skin care line products into the market. In October 2012, the Evonik announced to establish a new manufacturing unit for cosmetics and consumer goods in Brazil. This expansion initiative enables the company to expand global Consumer Specialties production network. In August 2012, the company started construction of methionine complex in Singapore to expand its capacity by 580,000 metric tons. It also announced to construct production facilities for feed amino acid L-lysine in Brazil and Russia. This allows the company to significantly expand its market position and competitive standing for the feed amino acid L-lysine. In April 2012, the company launched SPHINGOKINE, unique short-chain ceramide which stimulates the cross-talk between cells throughout the skin. It also introduced a new matting agent coil, sheet as well as decorative and industrial coatings. The company launched a comprehensive acrylic lens package known as PLEXIGLAS Solar Pre-fab lens panels that incorporate specialty PMMA molding compounds and sheet products for solar applications. Evonik also introduced a wetting and dispersing additive for curable coatings and printing inks. Furthermore, the company also launched world's strongest silicone and solvent-free deaerator for EP Floor coatings. In March 2012, the company offered a skin vitalizer of pentacyclic triterpenes under the brand TEGO Arjuna. Such expansion initiatives give an opportunity for the company to increase its revenues and market reach.

Threats

Highly Competitive Market

Increased competition may force the company to reduce its prices, which could negatively affect its margins. Evonik operates in a highly competitive chemical industry. The key competitive factors include product price, quality, distribution, innovation, skilled staff, application and others. Its key competitors include BASF SE, The Dow Chemical Company, Exxon Mobil Corporation, BASF, Clariant Chemicals and others. The company operates in a progressively more complex and challenging chemical marketplace whose dynamics is ever-changing. Technological advances by any player in the market could render its present or future products obsolete or uneconomical. The existing market includes companies of varying sizes; some more specialized than the company with respect to particular chemicals, and some with greater financial resources than the company.

Changes in Regulatory Environment

Evonik could be affected by the environmental regulations governing the global chemical industry. REACH (Registration Evaluation and Authorization of Chemicals) is an example of the stringent environmental regulations that are set to affect chemical producers. REACH regulates products manufactured and marketed in Europe. Phased over a period of 11 years, the regulation mandates all companies to develop and submit dossiers containing datasets about their chemical products and detail their potential impact and risk on environment. This will prove to be a challenge while launching new products as it is a time-consuming and expensive process. It may also result in phasing out many existing chemicals from the market, which may be regarded as toxic and hazardous. REACH directly applies to over 30,000 different chemical substances that are produced or sold in Europe and its implementation is expected to cost European chemical industry about USD 3 billion. Other countries too are expected to model their regulations after REACH. The US has already started implementing similar regulations with the reform of Toxic Substances Control Act. China has its own version of RoHS (Restriction of Hazardous Substances), which restricts the use of certain chemicals in the market. Also, environmental initiatives such as global responsible care and UN Global Compact could also impact the company’s business operations. Such regulations are set to get tightened in the coming years, affecting both the existing and new products.

Foreign Currency Fluctuations

As a global specialty chemical company, the company is active in over 100 countries globally and operate production plants in 24 countries. The robust international operations of the company increased its exposure to foreign currency fluctuations. Evonik has market presence throughout the world holding assets and liabilities sin foreign currencies. It transacts business in Chinese Renminbi, British Pound Sterling, Japanese Yen, US dollar, Swiss franc and Brazilian Real. However, the functional currency of the company’s operations is the EURO. The company makes efforts to mitigate risks through foreign currency hedging. However, hedging activities may not offset more than a portion of the adverse financial impact resulting from unfavorable movement in foreign currency exchange rates. Such fluctuations in currency would negatively impact the overall financial health of the company.

Corporate Family

Total Corporate Family Members: 158

Company Name	Company Type	Location	Country	Industry	Sales (USD mil)	Employees
RAG-Stiftung	Parent	Essen	Germany	Administration of Public Programs		30
Evonik Industries AG	Subsidiary	Essen	Germany	Synthetic Chemical Manufacturing	17,512.7	33,531
Asset/product line purchase by Temasek Holdings (Private) Limited proposed/announced.See corporate structure news on RAG-Stiftung for details
Evonik Degussa GmbH	Subsidiary	Essen, Nordrhein-Westfalen	Germany	Basic Chemical Manufacturing	6,601.9	38,000
Evonik Degussa Corporation	Subsidiary	Parsippany, NJ	United States	Basic Chemical Manufacturing		7,000
Evonik Degussa Corp. - Mobile	Facility	Theodore, AL	United States	Basic Chemical Manufacturing	254.7	800
Evonik Corp	Branch	Theodore, AL	United States	Miscellaneous Chemical Manufacturing	664.2	700
Evonik Jayhawk Fine Chemicals	Subsidiary	Galena, KS	United States	Miscellaneous Chemical Manufacturing	13.7	110
Evonik Degussa - Birmingham Labs	Division	Birmingham, AL	United States	Research and Development Services		90
Evonik Corp	Branch	Blair, NE	United States	Miscellaneous Chemical Manufacturing	79.3	86
Evonik Corp	Branch	Spring, TX	United States	Miscellaneous Chemical Manufacturing	91.1	60
Evonik Corp	Branch	Humble, TX	United States	Miscellaneous Chemical Manufacturing	91.1	60
Evonik Corp	Branch	Birmingham, AL	United States	Miscellaneous Chemical Manufacturing	56.9	60
Evonik Corp	Branch	Theodore, AL	United States	Miscellaneous Chemical Manufacturing	56.9	60
Evonik Corp	Branch	Burr Ridge, IL	United States	Miscellaneous Chemical Manufacturing	53.3	60
Evonik Corp	Branch	Lake Forest, CA	United States	Miscellaneous Chemical Manufacturing	46.5	60
Evonik Oil Additives USA Inc	Subsidiary	Horsham, PA	United States	Miscellaneous Chemical Manufacturing		60
Evonik Oil Additives USA	Branch	Deer Park, TX	United States	Miscellaneous Chemical Manufacturing	83.5	55
Evonik Degussa Corp. - Lockland	Facility	Cincinnati, OH	United States	Basic Chemical Manufacturing	143.3	50
Evonik Corp	Branch	Calvert City, KY	United States	Miscellaneous Chemical Manufacturing	55.1	50
Evonik Corp	Branch	Chester, PA	United States	Miscellaneous Chemical Manufacturing	41.3	50
Cyanco Company	Subsidiary	Winnemucca, NV	United States	Miscellaneous Chemical Manufacturing	9.9	50
Evonik Corp	Branch	Waterford, NY	United States	Miscellaneous Chemical Manufacturing	24.4	35
Evonik Corp	Branch	Kennesaw, GA	United States	Miscellaneous Chemical Manufacturing	16.0	20
Evonik Corp	Branch	Piscataway, NJ	United States	Miscellaneous Chemical Manufacturing	2.6	3
Evonik Corp	Branch	Vernon Hills, IL	United States	Miscellaneous Chemical Manufacturing	1.8	2
Degussa International Inc	Branch	Newark, DE	United States	Miscellaneous Chemical Manufacturing	1.7	1
Evonik Foams Inc	Subsidiary	Allen, TX	United States	Miscellaneous Chemical Manufacturing	12.9
Evonik Foams Inc	Branch	Magnolia, AR	United States	Miscellaneous Chemical Manufacturing	28.6	38
Evonik Degussa México, S.A. De C.V.	Subsidiary
Evonik Degussa México, S.A. De C.V.	Branch	Guadalajara, Jalisco	Mexico	Chemical Wholesale		15
Infracor GmbH	Subsidiary	Marl, Nordrhein-Westfalen	Germany	Miscellaneous Professional Services	1,367.7	3,280
Hüls Service GmbH	Subsidiary	Marl, Nordrhein-Westfalen	Germany	Hotels and Accommodation		143
Evonik Röhm GmbH	Subsidiary	Darmstadt, Hessen	Germany	Synthetic Chemical Manufacturing	1,687.4	3,000
Evonik Oil Additives GmbH	Subsidiary	Darmstadt, Hessen	Germany	Miscellaneous Chemical Manufacturing	276.8	170
Evonik Oil Additives Asia Pacific Pte. Ltd.	Subsidiary	Singapore	Singapore	Petroleum Product Manufacturing	150.6	90
Evonik Oil Additives	Subsidiary	Lauterbourg	France	Basic Chemical Manufacturing	72.0	34
Evonik Forhouse Optical Polymers Corp.	Subsidiary	Taichung City	Taiwan	Synthetic Chemical Manufacturing		50
Mönch-Kunststofftechnik GmbH	Subsidiary	Bad König, Hessen	Germany	Rubber and Plastic Product Manufacturing		22
Rohm America LLC	Subsidiary	Piscataway, NJ	United States	Basic Chemical Manufacturing
Evonik Degussa GmbH - Coatings & Additives, Hanau	Unit	Hanau	Germany	Synthetic Chemical Manufacturing		1,700
Evonik Goldschmidt GmbH	Subsidiary	Essen, Nordrhein-Westfalen	Germany	Basic Chemical Manufacturing	964.4	1,450
Evonik TEGO Chemie GmbH	Subsidiary	Essen, Nordrhein-Westfalen	Germany	Chemical Wholesale	208.6	240
Evonik Goldschmidt Corporation	Subsidiary	Hopewell, VA	United States	Basic Chemical Manufacturing		200
Evonik Goldschmidt Corp	Branch	Hopewell, VA	United States	Miscellaneous Chemical Manufacturing	76.2	100
Evonik Goldschmidt Corp	Branch	Janesville, WI	United States	Miscellaneous Chemical Manufacturing	58.3	76
Evonik Goldschmidt Corp	Branch	Mapleton, IL	United States	Miscellaneous Chemical Manufacturing	12.4	14
Evonik Goldschmidt Corp	Branch	Plymouth, WI	United States	Miscellaneous Chemical Manufacturing	0.8	1
Evonik Hanse GmbH	Subsidiary	Geesthacht, Schleswig-Holstein	Germany	Rubber and Plastic Product Manufacturing	36.2	85
Evonik Gorapur GmbH	Subsidiary	Wittenburg, Mecklenburg-Vorpommern	Germany	Miscellaneous Chemical Manufacturing		32
Evonik Degussa Antwerpen	Subsidiary	Lillo	Belgium	Basic Chemical Manufacturing	640.4	1,053
Industriepark Wolfgang GmbH	Subsidiary	Hanau, Hessen	Germany	Accounting and Tax Preparation	201.9	955
Evonik Cyro LLC	Subsidiary	Parsippany, NJ	United States	Synthetic Chemical Manufacturing		700
Evonik Cyro LLC	Branch	Sanford, ME	United States	Miscellaneous Chemical Manufacturing	215.8	340
Evonik Cyro LLC	Branch	Osceola, AR	United States	Miscellaneous Chemical Manufacturing	60.2	80
Evonik Cyro LLC	Branch	Effingham, IL	United States	Miscellaneous Chemical Manufacturing	53.3	60
Evonik Cyro LLC	Branch	Rockaway, NJ	United States	Miscellaneous Chemical Manufacturing	51.5	60
Evonik Cyro LLC	Branch	Glenmoore, PA	United States	Miscellaneous Chemical Manufacturing	49.5	60
Evonik Cyro LLC	Branch	Hebron, CT	United States	Miscellaneous Chemical Manufacturing	42.0	60
Evonik Cyro LLC	Branch	Sarasota, FL	United States	Miscellaneous Chemical Manufacturing	40.5	60
Evonik Cyro LLC	Branch	Limington, ME	United States	Miscellaneous Chemical Manufacturing	38.1	60
Evonik Cyro LLC	Branch	San Ramon, CA	United States	Miscellaneous Chemical Manufacturing	2.3	3
Evonik Cyro LLC	Branch	Olathe, KS	United States	Miscellaneous Chemical Manufacturing	2.0	2
Evonik Oxeno GmbH	Subsidiary	Marl, Nordrhein-Westfalen	Germany	Miscellaneous Chemical Manufacturing		418
Evonik Khimiya Ooo	Subsidiary	Moscow	Russian Federation	Architecture and Engineering	35.0	369
Li-Tec Battery GmbH	Subsidiary	Kamenz, Sachsen	Germany	Electrical Equipment and Appliances Manufacturing	9.5	300
Evonik Degussa Brazil Ltda.	Subsidiary	São Paulo, SP	Brazil	Synthetic Chemical Manufacturing	298.0	280
Evonik Rexim SAS	Subsidiary	Ham	France	Pharmaceutical Manufacturing	60.3	261
Korea Carbon Black Co., Ltd.	Subsidiary	Incheon	Korea, Republic of	Basic Chemical Manufacturing		250
AQura GmbH	Subsidiary	Hanau, Hessen	Germany	Miscellaneous Personal Services		220
Evonik Degussa Taiwan Ltd	Subsidiary	Taipei	Taiwan	Basic Chemical Manufacturing		200
Evonik Degussa International AG	Subsidiary	Zürich	Switzerland	Chemical Wholesale	12,413.7	180
Evonik Degussa International Ag, Organizacna Zlozka	Subsidiary	Bratislava - Mestska Cast Star	Slovakia	Chemical Wholesale		1
Evonik Agroferm Fermentációipari Zrt	Subsidiary	Kaba	Hungary	Basic Chemical Manufacturing	57.7	152
Evonik Technochemie GmbH	Subsidiary	Dossenheim, Baden-Württemberg	Germany	Basic Chemical Manufacturing	59.9	145
Insilco Ltd.	Subsidiary	Noida, Uttar Pradesh	India	Basic Chemical Manufacturing	15.2	138
Egesil Kimya Sanayi Ve Ticaret A S	Subsidiary	Istanbul (Europe)	Turkey	Basic Chemical Manufacturing	52.4	136
Evonik Litarion GmbH	Subsidiary	Kamenz, Sachsen	Germany	Machinery and Equipment Manufacturing	10.5	126
Evonik United Silica Industrial Ltd.	Subsidiary	Tayuan Hsiang, Taoyuan	Taiwan	Basic Chemical Manufacturing		120
Evonik Degussa Peroxid GmbH	Subsidiary	Weissenstein	Austria	Basic Chemical Manufacturing	42.2	101
Evonik (SEA) Pte Ltd	Subsidiary	Singapore	Singapore	Miscellaneous Wholesale		100
Evonik Degussa Italia s.p.a.	Subsidiary	Ravenna	Italy	Miscellaneous Chemical Manufacturing		99
Evonik Indonesia, Pt	Subsidiary	Bekasi, West Java	Indonesia	Basic Chemical Manufacturing	9.7	74
Evonik Sumi Asih, Pt	Subsidiary	Bekasi, West Java	Indonesia	Basic Chemical Manufacturing		69
Evonik Degussa Ibérica, S.A.	Subsidiary	Granollers, Barcelona	Spain	Chemical Wholesale	65.2	67
Evonik Degussa Argentina S.A.	Subsidiary	Buenos Aires	Argentina	Semiconductor and Other Electronic Component Manufacturing	19.8	40
CyPlus GmbH	Subsidiary	Hanau, Hessen	Germany	Miscellaneous Chemical Manufacturing	98.4	57
Evonik Silquimica Sa	Subsidiary	Lantaron, Alava	Spain	Basic Chemical Manufacturing	23.9	57
Degussa Brasil Ltda	Subsidiary	Sao Paulo, Sao Paulo	Brazil	Chemical Wholesale	289.0	50
Evonik Degussa Korea Ltd.	Subsidiary	Inchon, Inchon	Korea, Republic of	Chemical Wholesale	34.8	49
Evonik Degussa Canada Inc.	Subsidiary	Brampton, ON	Canada	Paint, Coating, and Adhesive Manufacturing		35
Evonik Degussa UK Services Limited	Subsidiary	Milton Keynes	United Kingdom	Miscellaneous Chemical Manufacturing		20
Evonik Degussa Praha s.r.o.	Subsidiary	Prague	Czech Republic	Miscellaneous Chemical Manufacturing		16
Evonik Degussa Hong Kong Ltd	Subsidiary	Hong Kong	Hong Kong	Chemical Wholesale		15
JSSi GmbH	Subsidiary	Freiberg, Sachsen	Germany	Metal Products Manufacturing	31.0	5
Evonik Degussa Croatia d.o.o.	Subsidiary	Zagreb	Croatia	Miscellaneous Chemical Manufacturing		5
Studiengesellschaft Kohle mit beschränkter Haftung	Subsidiary	Mülheim An Der Ruhr, Nordrhein-Westfalen	Germany	Research and Development Services		2
Goldschmidt SKW Surfactants GmbH	Subsidiary	Essen, Nordrhein-Westfalen	Germany	Holding Companies		2
Evonik Peroxygens Holding GmbH	Subsidiary	Essen, Nordrhein-Westfalen	Germany	Metal Products Manufacturing		2
Evonik Degussa Japan Co. Ltd.	Subsidiary	Osaka	Japan	Miscellaneous Chemical Manufacturing	163.0
Daicel-Evonik Ltd.	Joint Venture	Tokyo	Japan	Synthetic Chemical Manufacturing		25
Insilco Limited	Subsidiary	New Delhi, Delhi	India	Basic Chemical Manufacturing	13.8
Insilco Ltd	Branch	Noida	India	Basic Chemical Manufacturing	15.0	138
Evonik Degussa Immobilien Gmbh & Co. Kg	Subsidiary	Marl, Nordrhein-Westfalen	Germany	Real Estate Agents and Brokers	4.8
Westgas GmbH	Subsidiary	Marl, Nordrhein-Westfalen	Germany	Holding Companies		4
Degussa Skw Co	Subsidiary	Milton Keynes	United Kingdom	Miscellaneous Professional Services
Evonik Industries Greater China	Subsidiary	Beijing	China	Basic Chemical Manufacturing
Degussa Homogeneous Catalysts	Subsidiary	Hanau	Germany	Miscellaneous Chemical Manufacturing
Evonik Degussa Africa (Pty) Ltd	Subsidiary	Midrand, Gauteng	South Africa	Miscellaneous Chemical Manufacturing
RÃœTGERS GmbH	Subsidiary	Essen, Nordrhein-Westfalen	Germany	Holding Companies		10,928
RÃœTGERS Dienstleistungs-GmbH	Subsidiary	Essen, Nordrhein-Westfalen	Germany	Employment Services	2.5	125
RÃœTGERS Rail Verwaltungs GmbH	Subsidiary	Essen, Nordrhein-Westfalen	Germany	Motor Vehicle Parts Manufacturing		3
Evonik Services GmbH	Subsidiary	Essen, Nordrhein-Westfalen	Germany	Holding Companies		2,000
Evonik Industries AG - Feed Additives	Unit	Hanau	Germany	Food Manufacturing	654.9	1,700
Evonik Industries AG - Krefeld Plant	Facility	Krefeld	Germany	Miscellaneous Chemical Manufacturing		657
Evonik Stockhausen, LLC	Subsidiary	Greensboro, NC	United States	Basic Chemical Manufacturing	55.8	500
Evonik Stockhausen, LLC - Garyville	Subsidiary	Garyville, LA	United States	Chemical Wholesale	190.0	62
HVG Grünflächenmanagement GmbH	Subsidiary	Gelsenkirchen, Nordrhein-Westfalen	Germany	Crop and Animal Production	42.1	350
RHZ Handwerks-Zentrum GmbH	Subsidiary	Gelsenkirchen, Nordrhein-Westfalen	Germany	Specialty Construction Trade Contractors	31.1	280
Evonik Fermas s.r.o.	Subsidiary	Slovenská L'upca	Slovakia	Basic Chemical Manufacturing	58.6	250
Evonik Industries Ag	Branch	Münchsmünster, Bayern	Germany	Miscellaneous Chemical Manufacturing		183
RAG Verkauf GmbH	Subsidiary	Herne, Nordrhein-Westfalen	Germany	Basic Chemical Manufacturing	265.0	90
WSA GmbH	Subsidiary	Herne, Nordrhein-Westfalen	Germany	Photographic Services	16.9	14
Evonik Risk and Insurance Service GmbH	Subsidiary	Essen, Nordrhein-Westfalen	Germany	Holding Companies	15.6	40
MB Kroger Greifertechnik GmbH Co. & KG	Subsidiary	Sonsbeck, Nordrhein-Westfalen	Germany	Machinery and Equipment Manufacturing		40
Cosmoferm B.V.	Subsidiary	Delft	Netherlands	Miscellaneous Chemical Manufacturing		5
RBV Verwaltungs-GmbH	Subsidiary	Marl, Nordrhein-Westfalen	Germany	Holding Companies		3
R & B Industrieanlagenverwertung GmbH	Subsidiary	Essen, Nordrhein-Westfalen	Germany	Motor Vehicle and Parts Dealers		2
RCIV Vermögensverwaltungs-GmbH	Subsidiary	Essen, Nordrhein-Westfalen	Germany	Investment Services		1
Knipping System-Technik GmbH	Subsidiary	Halle, Saale	Germany	Metal Products Manufacturing		2
Evonik Projekt-Beteiligungs-GmbH & Co. KG	Subsidiary	Essen, Nordrhein-Westfalen	Germany	Holding Companies
Evonik Industries Ag	Branch	Darmstadt, Hessen	Germany	Synthetic Chemical Manufacturing
Evonik Industries Ag	Branch	Herne, Nordrhein-Westfalen	Germany	Miscellaneous Chemical Manufacturing
RAG Aktiengesellschaft	Subsidiary	Herne, Nordrhein-Westfalen	Germany	Coal Mining	3,610.9	21,458
RAG Deutsche Steinkohle AG	Subsidiary	Herne, Nordrhein-Westfalen	Germany	Holding Companies		24,000
RAG Anthrazit Ibbenbüren GmbH	Subsidiary	Ibbenbüren, Nordrhein-Westfalen	Germany	Coal Mining	502.7	2,450
Evonik Goldschmidt Rewo GmbH	Subsidiary	Steinau, Hessen	Germany	Metal Products Manufacturing	142.8	216
Evonik Immobilien GmbH	Subsidiary	Gelsenkirchen, Nordrhein-Westfalen	Germany	Pensions and Funds	574.8	70
Auguste Victoria GmbH	Subsidiary	Marl, Nordrhein-Westfalen	Germany	Residential and Commercial Building Construction	37.9	3,000
Wohnungsbaugesellschaft mit beschränkter Haftung Glückauf	Subsidiary	Moers, Nordrhein-Westfalen	Germany	Residential and Commercial Building Construction	20.0	111
EBV Gesellschaft mit beschränkter Haftung	Subsidiary	Hückelhoven, Nordrhein-Westfalen	Germany	Residential and Commercial Building Construction	23.1	42
Aachener Bergmannssiedlungsges. Mbh	Subsidiary	Hückelhoven, Nordrhein-Westfalen	Germany	Residential Real Estate Leasing	5.9	19
Heinrich Schäfermeyer GmbH	Subsidiary	Hückelhoven, Nordrhein-Westfalen	Germany	Real Estate Agents and Brokers		5
SJ Brikett- und Extrazitfabriken GmbH	Subsidiary	Hückelhoven, Nordrhein-Westfalen	Germany	Petroleum Product Manufacturing		2
Rhein Lippe Wohnen GmbH	Subsidiary	Duisburg, Nordrhein-Westfalen	Germany	Real Estate Agents and Brokers	60.0	40
Siedlung Niederrhein GmbH	Subsidiary	Dinslaken, Nordrhein-Westfalen	Germany	Residential and Commercial Building Construction		3
EBV GmbH	Subsidiary	Essen	Germany	Pensions and Funds		20
Wohnbau Westfalen GmbH	Subsidiary	Dortmund, Nordrhein-Westfalen	Germany	Real Estate Agents and Brokers	41.4	3
Lünener Wohnungs- und Siedlungsgesellschaft mit beschränkter Haftung	Subsidiary	Lünen, Nordrhein-Westfalen	Germany	Property Managers		5
Bauverein Glückauf GmbH	Subsidiary	Ahlen, Nordrhein-Westfalen	Germany	Residential and Commercial Building Construction
REMONDIS Industrie Service Süd GmbH & Co. KG.	Subsidiary	Rastatt, Baden-Württemberg	Germany	Trucking		49
Ege Kimya Sanayi ve Ticaret AS	Joint Venture	Istanbul	Turkey	Chemical Wholesale
Polifen Kimya Sanayii Ve Ticaret A S	Subsidiary	Istanbul (Europe)	Turkey	Synthetic Chemical Manufacturing	6.2	140
Steag State Power Inc.	Subsidiary	Makati	Philippines	Electricity Generation and Distribution
RAG Montan Immobilien GmbH	Subsidiary	Essen, Nordrhein-Westfalen	Germany	Real Estate Agents and Brokers	71.6	356
Evonik Carbon Black Nederland B.V.	Subsidiary	Amsterdam Zuidoost, Noord-Holland	Netherlands	Basic Chemical Manufacturing	7.9	99
Evonik Degussa Italia SpA	Subsidiary	Pandino	Italy	Synthetic Chemical Manufacturing	43.5	81
Aerosil France	Subsidiary	Salaise Sur Sanne	France	Chemical Wholesale		34
Evonik Degussa Africa (Pty) Ltd	Subsidiary	Halfway House, Gauteng	South Africa	Chemical Wholesale	41.0	26

Competitors Report

CompanyName	Location	Employees	Ownership
Akzo Nobel N.V.	Amsterdam, Netherlands	55,590	Public
Altana AG	Wesel, Nordrhein-Westfalen, Germany	5,363	Public
BASF SE	Ludwigshafen Am Rhein, Germany	112,617	Public
ExxonMobil Chemical Company	Houston, Texas, United States	14,000	Private
H.C. Starck Gmbh	Munchen, Germany	2,926	Private
Johnson Matthey PLC	London, United Kingdom	10,605	Public
The Dow Chemical Company	Midland, Michigan, United States	52,714	Public

Executives Report

Board of Directors

Name	Title	Function
Klaus Engel	Chairman of the Executive Board, Chief Executive Officer	Chairman
Biography: Dr. Klaus Engel has been Chairman of the Executive Board and Chief Executive Officer of Evonik Industries AG since January 1, 2009. Before that, he served as Member of the Executive Board at the Company. Dr. Engel was also Chairman of the Board of Management of Evonik Degussa GmbH and acted as Chairman of the Management Board of Degussa AG between 2006 and 2008. From 2006 to 2007, he was active as Member of the Management Board at RAG Aktiengesellschaft. Previously, between 1999 and 2006, Dr. Engel was Member of the Management Board of Brenntag AG, including the position of Chairman of the Management Board at Brenntag AG from 2001 as well as Chief Executive Director of Brenntag Management GmbH from March 2004. He served as Managing Director of Creanova Spezialchemie GmbH at Marl Stinnes AG from 1998 until 1999. He is also active within the Boards of Vivawest GmbH and STEAG GmbH. Dr. Engel earned a degree in Chemistry from Ruhr-Universitaet Bochum in 1980 and gained a Doctorate from Ruhr-Universitaet Bochum in 1984. Age: 57 Education: Ruhr-Universitaet Bochum, DS uhr-Universitaet Bochum (Chemistry)
Werner Mueller	Chairman of the Supervisory Board	Chairman
Biography: Dr. Werner Mueller has been Chairman of the Supervisory Board of Evonik Industries AG since December 1, 2012. He is also Chairman of the Executive Board of RAG-Stiftung, and chairs the Supervisory Boards of RAG Aktiengesellschaft and RAG Deutsche Steinkohle AG. Dr. Mueller also acts as Member of the Board of Contilia GmbH and Stadler Rail AG.
Werner Bischoff	Vice Chairman-Supervisory Board, Supervisory Board of Directors	Vice-Chairman
Michael Vassiliadis	Deputy Chairman of the Supervisory Board	Deputy Chairman
Biography: Mr. Michael Vassiliadis has served as Deputy Chairman of the Supervisory Board of Evonik Industries AG since September 26, 2012. He is Chairman fo the Mining, Chemical and Energy Industrial Union (IG BCE). Mr. Vassiliadis also serves on the Supervisory Boards of K + S AG, STEAG GmbH, BASF SE, Henkel-AG & Co. KGaA, and RAG-Stiftung. Age: 49
Peter Bettermann	Member of the Supervisory Board	Director/Board Member
Biography: Dr. Peter Bettermann is Member of the Supervisory Board of Evonik Industries AG. He is also a former Management Board Spokesman of Freudenberg Co KG. In addition, he serves as Chairman of the Supervisory Board of BATIG Gesellschaft fuer Beteiligungen GmbH, British American Tobacco (Germany) GmbH, as well as Member on the Supervisory Board of British American Tobacco (Industries) GmbH. He is also active within the Board of Wilh. Werhahn KG. Age: 65
Wilhelm Bonse-Geuking	Supervisory Board of Directors	Director/Board Member
Karin Erhard	Member of the Supervisory Board	Director/Board Member
Biography: Ms. Karin Erhard has been Member of the Supervisory Board of Evonik Industries AG since November 14, 2012, She is Head of the Department for Collective Bargaining Law and Pay-Scale Planning of the Mining, Chemical and Energy Industrial Union (IG BCE). Ms. Erhard also serves on the Supervisory Boards of INEOS Deutschland GmbH and INEOS Koeln GmbH.
Hans Michael Gaul	Member of the Supervisory Board	Director/Board Member
Biography: Dr. Hans Michael Gaul is Member of the Supervisory Board of Evonik Industries AG. He also sits on the Supervisory Boards of BDO AG, HSBC Trinkaus & Burkhardt AG, and Siemens AG. Age: 71
Stephan Gemkow	Member of the Supervisory Board	Director/Board Member
Biography: Mr. Stephan Gemkow is Member of the Supervisory Board of Evonik Industries AG. Furthermore, he serves as Chairman of Celesio AG and TAKKT AG. He is also on the Boards of Amadeus IT Group S.A., Amadeus IT Holding S.A., and JetBlue Airways Corporation. Age: 53
Ralf Giesen	Member of the Supervisory Board	Director/Board Member
Biography: Mr. Ralf Giesen is Member of the Supervisory Board of Evonik Industries AG. Furthermore, he acts as Secretary of the Board of the Mining, Chemical and Energy Industrial Union. He is Member of the Supervisory Board of Altana AG.
Barbara Grunewald	Member of the board of directors	Director/Board Member
Adam Guenter	Member of the Supervisory Board	Director/Board Member
Biography: Mr. Adam Guenter acts as Member of the Supervisory Board at Evonik Industries AG. He is Chairman of the Group Works at the Company's facility in Hanau and Deputy Chairman of the Central Works Council of Evonik Inudistries AG.
Thomas Haeberle	Member of the Executive Board	Director/Board Member
Biography: Dr. Thomas Haeberle has been Member of the Executive Board of Evonik Industries AG since April 1, 2011. He studied process technology at Universitaet Erlangen- Nuremberg where he was awarded a doctorate in Engineering. Dr. Haeberle started his career at Roehm GmbH in Darmstadt, where he was responsible for the monomers business and PLEXIGLAS molding compounds. In 2003 he moved from Roehm GmbH to take up a post on the Board of Management of Infracor GmbH, becoming its Chairman from 2004 until 2006. In 2006 he joined Degussa AG, initially as Head of the Building Blocks Business Unit. In 2008 he became Head of the Industrial Chemicals Business Unit at Evonik Degussa GmbH, a position he held until he was appointed to the Board of Management of Evonik Degussa GmbH in 2009. He serves on Board of Evonik Services GmbH. Age: 57 Education: University of Erlangen-Nuremberg, PHD (Engineering)
Ralf Hermann	Member of the Supervisory Board	Director/Board Member
Biography: Mr. Ralf Hermann is Member of the Supervisory Board of Evonik Industries AG. He is Chairman of the Central Works Council of Evonik Industries AG. He is also active within the RAG-Stiftung.
Wolfgang A. Herrmann	Member of the Supervisory Board	Director/Board Member
Biography: Prof. Dr. Wolfgang A. Herrmann is Member of the Supervisory Board of Evonik Industries AG. In addition, he acts as President of Technische Universitaet Muenchen. He is also Member of the Supervisory Board of Bayerische Forschungsallianz GmbH.
Dieter Kleren	Member of the Supervisory Board	Director/Board Member
Biography: Mr. Dieter Kleren has been Member of the Supervisory Board of Evonik Industries AG since August 1, 2011. He also serves as Chairman of the Works Council for the Wesseling facilities.
Steve Koltes	Member of the Supervisory Board	Director/Board Member
Biography: Mr. Steve Koltes is Member of the Supervisory Board of Evonik Industries AG. Furthermore, he serves as Managing Director of CVC Capital Partners Luxembourg S.a.r.C. He is also active on the Boards of Flint Group Investments S.à r.l., Flint Group S.à r.l. and Flint Group Holdings S.a.r.l. Education: Middlebury College, BA
Rainer Kumlehn	Supervisory Board of Directors	Director/Board Member
Siegfried Luther	Member of the Supervisory Board	Director/Board Member
Biography: Dr. Siegfried Luther is Member of the Supervisory Board of Evonik Industries AG. He is former Chief Financial Officer of Bertelsmann AG. In addition, he is Member of the Supervisory Board of Schaeffler AG and Sparkasse Guetersloh. He is also Chairman of the Board of RTL S.A. He holds a Juris Doctor degree in Law from Westfaelische Wilhelms-Universitaet Muenster. Age: 68 Education: Westfaelische Wilhelms-Universitaet Muenster, JD (Law)
Juergen Noeding	Member of the Supervisory Board	Director/Board Member
Biography: Mr. Juergen Noeding acts as Member of the Supervisory Board of Evonik Industries AG. Additionally, he serves as Chairman of the General Works Council at Evonik Services GmbH, where he also acts as Member of the Supervisory Board.
Norbert Pohlmann	Member of the Supervisory Board	Director/Board Member
Biography: Mr. Norbert Pohlmann has been Member of the Supervisory Board of Evonik Industries AG since August 1, 2011. He also serves as Chairman of the Works Council for the Goldschmidtstrasse facilities and is active on the Board of BKK Novitas.
Wilfried Robers	Member of the Supervisory Board	Director/Board Member
Biography: Dr. Wilfried Robers acts as Member of the Supervisory Board of Evonik Industries AG. He is Chairman of the Executive Staff Representation Committee at the Company. He is also active within the Pensionskasse Degussa VVaG.
Michael Rüdiger	Member of the board of directors	Director/Board Member
Christian H. Strenger	Member of the Supervisory Board	Director/Board Member
Biography: Mr. Christian H. Strenger is Member of the Supervisory Board of Evonik Industries AG. He is former Spokesman of the Supervisory Board of DWS Investment GmbH. He is Member of the Supervisory Board of DWS Investment GmbH, TUI AG and Fraport AG. He is also Chairman of the Board at The Germany Funds.
Ulrich Terbrack	Member of the Supervisory Board	Director/Board Member
Biography: Mr. Ulrich Terbrack has been Member of the Supervisory Board of Evonik Industries AG since March 12, 2011. He also serves as Deputy Chairman of the Central Works Council of Evonik Industries AG.
Volker Trautz	Member of the Supervisory Board	Director/Board Member
Biography: Dr. Volker Trautz is Member of the Supervisory Board of Evonik Industries AG. He is former Chairman of the Supervisory Board of LyondellBasell Industrie Holdings BV. He is Member of the Supervisory Board of Citigroup Global Markets Deutschland AG and is active on the Boards of CERONA Companhia de Energia Renovavel, OSF Merchant Banking and La Seda de Barcelona. Education: Universitaet Stuttgart, DS (Chemistry)
Thomas Wessel	Member of the Executive Board, Director of Human Resources	Director/Board Member
Biography: Mr. Thomas Wessel has been Member of the Executive Board and Director of Human Resources at Evonik Industries AG since September 1, 2011. Having qualified as an industrial clerk at Bergbau AG, he trained as a personnel officer and subsequently studied human resources management. Mr. Wessel began his career in the human resources department at Bergbau AG, Lippe, and subsequently moved to the Personnel Policy Issues Department at RAG Aktiengesellschaft, which he headed from 1997. From 2001 until 2002 his roles also included heading the Human Resources Division and the Human Resources Policy Department at RAG Aktiengesellschaft. From 2002 until 2006 he headed the Human Resources Division at RAG Aktiengesellschaft. During this time Mr. Wessel was also a member of the Board of Management of RAG Beteiligungs- GmbH. In 2006 he was appointed Chairman of the Board of Management of RAG BILDUNG GmbH. In 2009 he joined Evonik Degussa AG as Chief Human Resources Officer and a member of the Board of Management. He also serves as Chairman of the Board of Industriepark Wolfgang GmbH, Infracor GmbH and Member of the Board of Gesellschaft zur Sicherung von Bergmannswohnungen mbH and THS GmbH, among others. Age: 50
Christian Wildmoser	Member of the Supervisory Board	Director/Board Member
Biography: Dr. Christian Wildmoser is Member of the Supervisory Board of Evonik Industries AG. In addition, he acts as Managing Director of CVC Capital Partners Switzerland GmbH. He is also active within the Board at Flint Group Holdings S.a.r.l., Flint Group Investments S.a r.l. and Flint Group S.a r.l.
Patrik Wohlhauser	Member of the Executive Board	Director/Board Member
Biography: Mr. Patrik Wohlhauser has been Member of the Executive Board of Evonik Industries AG since April 1, 2011. He took a business administration degree at Universite de Fribourg followed by the Accelerated Management Development Programme at London Business School. At the start of his career Mr. Wohlhauser was employed in Operational Auditing at SANDOZ INTERNATIONAL AG. He was Operations Manager at MBT SCHWEIZ AG from 1993, and Director Sales at this company from 1995. In 1997 he was appointed CEO of MBT FRANCE. In 2002 he moved to Degussa AG, initially as head of the Construction Systems Europe Business Unit and from 2005 as head of the Exclusive Synthesis & Catalysts Business Unit. From 2007 he was a member of the Board of Management of Evonik Degussa GmbH, becoming Chairman in 2009. Age: 49 Education: Freiburg University (Business Administration)
Dahai Yu	Member of the Executive Board	Director/Board Member
Biography: Dr. Dahai Yu has been Member of the Executive Board of Evonik Industries AG since April 1, 2011. He studied chemistry at the Universitaet Hamburg, where he obtained his doctorate in 1989. Following a research scholarship, he joined Degussa AG as a laboratory manager in Central Research in 1990. His long career at Degussa included posts as product manager, director of the Corporate Development and Strategy Planning department, head of controlling for the Fine & Industrial Chemicals Business Unit and head of the Agrochemicals & Intermediates Business Line. In 2006 Dr. Yu returned to Shanghai as President of Evonik’s Greater China Region and Chairman of Evonik Degussa (China) Co., Ltd. Age: 52 Education: University of Hamburg, PHD (Chemistry)

Executives

Name	Title	Function
Klaus Engel	Chairman of the Executive Board, Chief Executive Officer	Chief Executive Officer
Biography: Dr. Klaus Engel has been Chairman of the Executive Board and Chief Executive Officer of Evonik Industries AG since January 1, 2009. Before that, he served as Member of the Executive Board at the Company. Dr. Engel was also Chairman of the Board of Management of Evonik Degussa GmbH and acted as Chairman of the Management Board of Degussa AG between 2006 and 2008. From 2006 to 2007, he was active as Member of the Management Board at RAG Aktiengesellschaft. Previously, between 1999 and 2006, Dr. Engel was Member of the Management Board of Brenntag AG, including the position of Chairman of the Management Board at Brenntag AG from 2001 as well as Chief Executive Director of Brenntag Management GmbH from March 2004. He served as Managing Director of Creanova Spezialchemie GmbH at Marl Stinnes AG from 1998 until 1999. He is also active within the Boards of Vivawest GmbH and STEAG GmbH. Dr. Engel earned a degree in Chemistry from Ruhr-Universitaet Bochum in 1980 and gained a Doctorate from Ruhr-Universitaet Bochum in 1984. Age: 57 Education: Ruhr-Universitaet Bochum, DS Ruhr-Universitaet Bochum (Chemistry)
John Rolando	President-Evonik Corp.	President
Gerard Berote	Managing Director Taiwan operations	Managing Director
Christian Kullmann	Executive Vice President, Head- General Secretariat	Senior Management (General)
Ute Wolf	Chief Financial Officer	Finance Executive
Thomas Wessel	Member of the Executive Board, Director of Human Resources	Human Resources Executive
Biography: Mr. Thomas Wessel has been Member of the Executive Board and Director of Human Resources at Evonik Industries AG since September 1, 2011. Having qualified as an industrial clerk at Bergbau AG, he trained as a personnel officer and subsequently studied human resources management. Mr. Wessel began his career in the human resources department at Bergbau AG, Lippe, and subsequently moved to the Personnel Policy Issues Department at RAG Aktiengesellschaft, which he headed from 1997. From 2001 until 2002 his roles also included heading the Human Resources Division and the Human Resources Policy Department at RAG Aktiengesellschaft. From 2002 until 2006 he headed the Human Resources Division at RAG Aktiengesellschaft. During this time Mr. Wessel was also a member of the Board of Management of RAG Beteiligungs- GmbH. In 2006 he was appointed Chairman of the Board of Management of RAG BILDUNG GmbH. In 2009 he joined Evonik Degussa AG as Chief Human Resources Officer and a member of the Board of Management. He also serves as Chairman of the Board of Industriepark Wolfgang GmbH, Infracor GmbH and Member of the Board of Gesellschaft zur Sicherung von Bergmannswohnungen mbH and THS GmbH, among others. Age: 50
Alexandra Boy	Press Officer	Public Relations Executive
Barbara Muller	Head-Press & Press Officer	Public Relations Executive
Edda Schulze	Press Officer	Public Relations Executive
Ruben Thiel	Press Officer	Public Relations Executive
Oliver Luckenbach	Head of Investor Relations	Investor Relations Executive
Johannes Pfleger	Chemist	Research & Development Executive
Biography: Johannes Pfleger first attended a middle school and then the Industrial School in Munich receiving a diploma in 1884. After completing his military service and a short stay in an infirmary following an accident he enrolled as a student in the Chemical-Technical Faculty at the Royal Technical University in Munich. Upon completion of his studies in 1891 (when a doctorate at a technical university was not yet possible) he joined Deutsche Gold- und Silber-Scheideanstalt (Degussa AG since 1980 and predecessor of the Chemicals Business Area of Evonik) in Frankfurt am Main as an industrial chemist. Just a year later as senior electronics chemist he took over the experimental facility for electrochemistry and electrometallurgy which was founded jointly by Degussa and Metallgesellschaft AG.
Jason Fox	Director, Oil and Gas Group	Planning Executive

Significant Developments

Evonik Industries AG to Appoint New CFO

May 29, 2013

Evonik Industries AG announced that the executive committee of the supervisory board of Evonik Industries AG has proposed to the supervisory board to give its consent to the amicable termination of the board position of Dr. Wolfgang Colberg as Chief Financial Officer (CFO) with effect to September 30, 2013 and to appoint Ms. Ute Wolf as chief CFO with effect from October 1, 2013.

Temasek Holdings To Buy Stake In Evonik Industries AG-Reuters

Mar 10, 2013

Reuters reported that Temasek Holdings will take a stake in Evonik Industries. Temasek will spend more than EUR600 million ($779 million) for 5% of the Essen-based chemicals company. German magazine Wirtschaftswoche reported on Saturday that Temasek and Evonik had agreed the sale. A spokesman for Temasek declined to confirm the deal.

News

Prize awarded to new membrane technology from Evonik; German Federal Environment Ministry and BDI acknowledge SEPURAN Green with the German Innovation Prize for Climate and the Environment ENP Newswire (670 Words)	05-Dec-2013
Evonik starts innovation campaign; Patrik Wohlhauser, Executive Board Member: 'We want to increase the value of our innovation pipeline even further.'; Evonik laboratories demonstrate feasibility of producing specialty chemicals from syngas using biotech production ENP Newswire (1007 Words)	04-Dec-2013
Evonik Industries: More clout for strategic research; Creavis to operate in new structure from 2014 onward; Sustainability as an innovation driver ENP Newswire (593 Words)	04-Dec-2013
Evonik: Bacteria like the taste of syngas ENP Newswire (775 Words)	04-Dec-2013
WIPO PUBLISHES PATENT OF EVONIK INDUSTRIES AG TITLED AS "DIRECT CURING OF REACTIVE RESINS BY MEANS OF PLASMA INDUCTION" Plus Patent News (519 Words)	02-Dec-2013
Findings from P. Morfeld et al in Silicosis Reported Health & Medicine Week (334 Words)	20-Nov-2013
Evonik positions itself in oncology ENP Newswire (528 Words)	18-Nov-2013
WIPO PUBLISHES PATENT OF EVONIK INDUSTRIES AG TITLED AS "MULTI-STAGE SYNTHESIS METHOD WITH SYNTHESIS GAS" Plus Patent News (224 Words)	16-Nov-2013
TEGO Twin 4200 - The new universal wetting and anti-cratering additive ENP Newswire (313 Words)	11-Nov-2013
Essen, Germany- Evonik provides drug formulation services for highly potent active pharmaceutical ingredients ENP Newswire (520 Words)	11-Nov-2013
For Men Only - New Men's Care concept developed by Evonik Evonik launches unique Men's Care concept ENP Newswire (517 Words)	08-Nov-2013

Annual Profit & Loss

	31-Dec-2012	31-Dec-2011	31-Dec-2010
Period Length	12 Months	12 Months	12 Months
Filed Currency	EUR	EUR	EUR
Exchange Rate (Period Average)	0.778237	0.71919	0.755078
Consolidated	Yes	Yes	Yes
Total income	17,512.7	20,217.2	17,614.1
Net sales	17,512.7	20,217.2	17,614.1
Other operating income	1,945.4	1,409.9	1,278.0
Cost of sales	12,464.1	14,248.0	12,502.0
Gross profit	5,048.6	5,969.2	5,112.1
Advertising, distribution, and commercial expenses	1,595.9	1,726.9	1,554.8
General expenses	831.4	921.9	834.4
Other operating costs	2,149.7	2,253.9	2,239.5
Net operating income	2,417.0	2,476.4	1,761.4
Other income	18.0	36.2	18.5
Interest payable on loans	503.7	599.3	597.3
Total expenses	326.4	439.4	479.4
Profit before tax	2,090.6	2,037.0	1,282.0
Provisions	5,648.7	6,942.5	8,216.4
Total taxation	591.1	627.1	231.8
Net profit	1,499.5	1,409.9	1,050.2

Annual Balance Sheet

Financials in: USD (mil)

	31-Dec-2012	31-Dec-2011	31-Dec-2010
Filed Currency	EUR	EUR	EUR
Exchange Rate	0.7566	0.770327	0.745406
Consolidated	Yes	Yes	Yes
Issued capital	615.9	604.9	625.2
Capital reserves	1,539.8	1,512.3	1,562.9
Profits for the year	7,007.7	5,929.9	5,296.4
Total stockholders equity	9,025.9	7,885.0	8,007.7
Minority interests	146.7	120.7	795.5
Deferred taxation	84.6	68.8	60.4
Other provisions	2,583.9	2,771.6	3,190.2
Provision for pensions	3,141.7	3,641.3	4,398.9
Provisions and allowances	5,810.2	6,481.7	8,323.0
Other debentures	943.7	1,119.0	1,179.2
Mortgages and loans	986.0	2,414.6	2,723.3
Taxes and social security	223.4	176.5	189.2
Total long-term liabilities	2,153.1	3,710.1	4,091.7
Trade creditors	1,448.6	1,409.8	1,459.6
Advances received	29.1	14.3	47.0
Bank loans and overdrafts	1,459.2	-	-
Other loans	498.3	515.4	407.8
Taxation and social security	576.3	858.1	4,707.5
Total current liabilities	4,011.4	2,797.5	6,621.9
Regularisation account	411.0	497.2	515.2
Total liabilities (including net worth)	22,023.5	21,995.9	27,559.5
Patents	535.3	562.1	684.2
Goodwill	3,580.5	3,562.1	3,842.2
Other intangibles	68.7	84.4	150.3
Intangibles	4,216.2	4,247.5	4,676.6
Land and buildings	3,694.2	3,675.1	3,852.9
Machinery and tools	2,906.4	2,965.0	3,186.2
Fixtures and equipment	3,694.2	3,675.1	3,852.9
Fixed assets under construction	1,128.7	791.9	770.0
Total tangible fixed assets	7,992.3	7,660.4	8,026.5
Participating interest	39.7	75.3	25.5
Deposits	89.9	122.0	116.7
Total financial assets	1,625.7	1,569.5	896.2
Total non-current assets	13,834.3	13,477.4	13,599.3
Raw materials	573.6	573.8	649.3
Work in progress	152.0	159.7	140.9
Finished goods	1,545.1	1,402.0	1,336.2
Net stocks and work in progress	2,270.7	2,135.5	2,126.4
Trade debtors	2,229.7	2,221.1	2,449.7
Other receivables	945.0	777.6	6,639.3
Total receivables	3,174.7	2,998.7	9,089.0
Cash and liquid assets	979.4	2,088.7	1,479.7
Short-term investments	1,226.5	582.9	520.5
Shares in associated companies	1,496.2	1,372.1	754.0
Recoverable taxation	434.8	619.2	694.9
Total current assets	7,651.3	7,805.8	13,215.6
Prepaid expenses and deferred costs	103.1	93.5	49.6
Total assets	22,023.5	21,995.9	27,559.5

Annual Ratios

Financials in: USD (mil)

	31-Dec-2012	31-Dec-2011	31-Dec-2010
Period Length	12 Months	12 Months	12 Months
Filed Currency	EUR	EUR	EUR
Exchange Rate	0.7566	0.770327	0.745406
Consolidated	Yes	Yes	Yes
Current ratio	19.07	27.90	19.96
Acid test ratio	13.41	20.27	16.75
Total liabilities to net worth	0.07%	0.08%	0.13%
Net worth to total assets	0.04%	0.04%	0.03%
Current liabilities to net worth	0.04%	0.04%	0.08%
Current liabilities to stock	0.18%	0.13%	0.31%
Fixed assets to net worth	0.15%	0.17%	0.17%
Collection period	453.00	431.00	500.00
Stock turnover rate	1.26	1.13	1.19
Profit margin	0.01%	0.01%	0.01%
Return on assets	0.01%	0.01%	0.01%
Shareholders' return	0.02%	0.02%	0.01%
Sales per employee	40.72	43.17	38.86
Profit per employee	3.49	3.01	2.32
Net worth	9,025.9	7,885.0	8,007.7
Number of employees	33,471	33,677	34,223

Annual Income Statement

Financials in: USD (mil)

Except for share items (millions) and per share items (actual units)

Financial Glossary

	31-Dec-2012	31-Dec-2011	31-Dec-2010	31-Dec-2009	31-Dec-2008
Period Length	12 Months	12 Months	12 Months	12 Months	12 Months
UpdateType/Date	Updated Normal 31-Dec-2012	Updated Normal 31-Dec-2011	Reclassified Normal 31-Dec-2011	Restated Normal 31-Dec-2010	Restated Normal 31-Dec-2009
Filed Currency	EUR	EUR	EUR	EUR	EUR
Exchange Rate (Period Average)	0.778237	0.71919	0.755078	0.719047	0.683679
Auditor	PricewaterhouseCoopers AG	PricewaterhouseCoopers AG	PricewaterhouseCoopers AG	PricewaterhouseCoopers LLP	PricewaterhouseCoopers LLP
Auditor Opinion	Unqualified	Unqualified	Unqualified	Unqualified	Unqualified
Net Sales	17,512.7	21,617.4	18,881.5	15,809.8	24,725.0
Revenue	17,512.7	21,617.4	18,881.5	15,809.8	24,725.0
Interest Income, Non-Bank	-	19.5	14.6	-	-
Other Revenue, Total	-	19.5	14.6	-	-
Total Revenue	17,512.7	21,636.9	18,896.1	15,809.8	24,725.0
Cost of Revenue	12,464.1	14,248.0	12,502.0	10,750.3	18,113.8
Cost of Revenue, Total	12,464.1	14,248.0	12,502.0	10,750.3	18,113.8
Gross Profit	5,048.6	7,369.4	6,379.5	5,059.5	6,611.3
Selling/General/Administrative Expense	2,427.3	3,186.9	2,998.4	3,645.1	4,613.3
Total Selling/General/Administrative Expenses	2,427.3	3,186.9	2,998.4	3,645.1	4,613.3
Research & Development	505.0	507.5	447.6	414.4	454.9
Investment Income - Operating	-	837.1	921.8	-	-
Interest/Investment Income - Operating	-	837.1	921.8	-	-
Interest Expense (Income) - Net Operating Total	-	837.1	921.8	-	-
Restructuring Charge	-	11.1	41.1	82.1	92.1
Impairment-Assets Held for Use	-	239.2	190.7	175.2	465.1
Loss (Gain) on Sale of Assets - Operating	-	52.8	21.2	12.5	-172.6
Other Unusual Expense (Income)	-	-	-	-	-29.3
Unusual Expense (Income)	-	303.1	253.0	269.8	355.4
Other Operating Expense	1,657.6	-	-	-	-
Other, Net	-1,953.1	-	-	-	-
Other Operating Expenses, Total	-295.5	-	-	-	-
Total Operating Expense	15,100.8	19,082.6	17,122.7	15,079.7	23,537.4
Operating Income	2,411.9	2,554.3	1,773.3	730.1	1,187.7
Interest Expense - Non-Operating	-503.7	-344.8	-323.1	-596.6	-886.4
Interest Expense, Net Non-Operating	-503.7	-344.8	-323.1	-596.6	-886.4
Interest Income - Non-Operating	45.0	69.5	30.5	44.5	111.2
Investment Income - Non-Operating	111.8	111.2	71.5	79.3	93.6
Interest/Investment Income - Non-Operating	156.8	180.8	102.0	123.8	204.8
Interest Income (Expense) - Net Non-Operating Total	-346.9	-164.1	-221.2	-472.8	-681.6
Other Non-Operating Income (Expense)	6.4	-244.7	-260.9	5.6	23.4
Other, Net	6.4	-244.7	-260.9	5.6	23.4
Income Before Tax	2,071.3	2,145.5	1,291.3	262.8	529.5
Total Income Tax	591.1	627.1	231.8	75.1	187.2
Income After Tax	1,480.3	1,518.4	1,059.5	187.7	342.3
Minority Interest	-3.9	-4.2	-78.1	-100.1	-102.4
Net Income Before Extraord Items	1,476.4	1,514.2	981.4	87.6	239.9
Discontinued Operations	19.3	-108.5	-9.3	246.2	171.1
Total Extraord Items	19.3	-108.5	-9.3	246.2	171.1
Net Income	1,495.7	1,405.7	972.1	333.8	411.0
Income Available to Common Excl Extraord Items	1,476.4	1,514.2	981.4	87.6	239.9
Income Available to Common Incl Extraord Items	1,495.7	1,405.7	972.1	333.8	411.0
Basic/Primary Weighted Average Shares	466.0	466.0	464.6	466.0	466.0
Basic EPS Excl Extraord Items	3.17	3.25	2.11	0.19	0.51
Basic/Primary EPS Incl Extraord Items	3.21	3.02	2.09	0.72	0.88
Dilution Adjustment	-	-	-	0.0	-
Diluted Net Income	1,495.7	1,405.7	972.1	333.8	411.0
Diluted Weighted Average Shares	466.0	466.0	464.6	466.0	466.0
Diluted EPS Excl Extraord Items	3.17	3.25	2.11	0.19	0.51
Diluted EPS Incl Extraord Items	3.21	3.02	2.09	0.72	0.88
Dividends per Share - Common Stock Primary Issue	-	1.27	1.14	0.96	0.00
Gross Dividends - Common Stock	-	590.9	529.7	-	0.0
Interest Expense, Supplemental	503.7	344.8	323.1	596.6	886.4
Depreciation, Supplemental	1,028.0	707.7	819.8	860.9	947.8
Total Special Items	-	329.5	238.4	269.8	355.4
Normalized Income Before Tax	2,071.3	2,475.0	1,529.6	532.6	884.9
Effect of Special Items on Income Taxes	-	96.3	42.8	77.1	125.7
Inc Tax Ex Impact of Sp Items	591.1	723.4	274.6	152.2	312.9
Normalized Income After Tax	1,480.3	1,751.6	1,255.1	380.5	572.0
Normalized Inc. Avail to Com.	1,476.4	1,747.4	1,177.0	280.3	469.6
Basic Normalized EPS	3.17	3.75	2.53	0.60	1.01
Diluted Normalized EPS	3.17	3.75	2.53	0.60	1.01
Amort of Intangibles, Supplemental	-	130.7	151.0	187.7	220.9
Rental Expenses	-	129.3	123.2	-	-
Research & Development Exp, Supplemental	505.0	507.5	447.6	414.4	454.9
Normalized EBIT	2,411.9	3,720.9	2,933.5	999.9	1,543.1
Normalized EBITDA	3,439.8	4,559.3	3,904.2	2,048.5	2,711.8
Current Tax - Domestic	-	545.1	529.7	-	188.7
Current Tax - Total	-	545.1	529.7	-	188.7
Deferred Tax - Domestic	-	82.0	-298.0	-	-1.5
Deferred Tax - Total	-	82.0	-298.0	-	-1.5
Income Tax - Total	-	627.1	231.8	-	187.2
Interest Cost - Domestic	463.9	504.7	495.3	521.5	555.8
Service Cost - Domestic	152.9	148.8	123.2	118.2	146.3
Expected Return on Assets - Domestic	-253.1	-250.3	-221.2	-218.3	-241.3
Curtailments & Settlements - Domestic	0.0	8.3	11.9	0.0	-1.5
Other Pension, Net - Domestic	24.4	29.2	111.2	30.6	49.7
Domestic Pension Plan Expense	388.1	440.8	520.5	452.0	509.0
Defined Contribution Expense - Domestic	-	-	-	-	231.1
Defined Contribution Expense - Foreign	-	-	-	-	13.2
Total Pension Expense	388.1	440.8	520.5	452.0	753.3
Discount Rate - Domestic	3.75%	4.75%	5.00%	5.50%	6.00%
Discount Rate - Foreign	3.78%	4.76%	5.03%	5.54%	6.02%
Expected Rate of Return - Domestic	4.71%	4.80%	4.93%	5.00%	5.00%
Expected Rate of Return - Foreign	4.86%	5.05%	5.35%	5.35%	5.41%
Compensation Rate - Domestic	2.50%	2.50%	2.54%	2.53%	2.53%
Compensation Rate - Foreign	2.58%	2.60%	2.62%	2.63%	2.68%
Pension Payment Rate - Domestic	2.00%	2.00%	2.00%	2.00%	2.00%
Pension Payment Rate - Foreign	1.99%	2.02%	2.06%	2.07%	2.02%
Total Plan Interest Cost	463.9	504.7	495.3	521.5	555.8
Total Plan Service Cost	152.9	148.8	123.2	118.2	146.3
Total Plan Expected Return	-253.1	-250.3	-221.2	-218.3	-241.3
Total Plan Other Expense	24.4	29.2	111.2	30.6	49.7

Annual Balance Sheet

Financials in: USD (mil)

Financial Glossary

	31-Dec-2012	31-Dec-2011	31-Dec-2010	31-Dec-2009	31-Dec-2008
UpdateType/Date	Reclassified Normal 30-Sep-2013	Reclassified Normal 31-Dec-2012	Updated Normal 31-Dec-2010	Updated Normal 31-Dec-2009	Restated Normal 31-Dec-2009
Filed Currency	EUR	EUR	EUR	EUR	EUR
Exchange Rate	0.7566	0.770327	0.745406	0.696986	0.719399
Auditor	PricewaterhouseCoopers AG	PricewaterhouseCoopers AG	PricewaterhouseCoopers AG	PricewaterhouseCoopers LLP	PricewaterhouseCoopers LLP
Auditor Opinion	Unqualified	Unqualified	Unqualified	Unqualified	Unqualified
Cash & Equivalents	979.4	1,829.1	1,479.7	1,269.8	745.1
Short Term Investments	1,435.4	893.1	649.3	430.4	458.7
Cash and Short Term Investments	2,414.8	2,722.2	2,129.0	1,700.2	1,203.8
Accounts Receivable - Trade, Gross	-	-	2,459.1	-	-
Provision for Doubtful Accounts	-	-	-9.4	-	-
Trade Accounts Receivable - Net	2,229.7	2,221.1	2,449.7	3,081.8	3,575.2
Other Receivables	589.5	542.6	320.6	604.0	735.3
Total Receivables, Net	2,819.2	2,763.8	2,770.3	3,685.9	4,310.5
Inventories - Finished Goods	-	-	1,336.2	1,251.1	1,915.5
Inventories - Work In Progress	-	-	140.9	210.9	208.5
Inventories - Raw Materials	-	-	649.3	819.2	928.6
Total Inventory	2,270.7	2,135.5	2,126.4	2,281.3	3,052.5
Prepaid Expenses	-	-	87.2	134.9	-
Discontinued Operations - Current Asset	44.9	61.0	6,039.7	0.0	286.4
Other Current Assets, Total	44.9	61.0	6,039.7	0.0	286.4
Total Current Assets	7,549.6	7,682.5	13,152.6	7,802.2	8,853.2
Buildings	-	-	3,910.6	4,817.9	4,585.8
Machinery/Equipment	-	-	15,630.4	20,428.0	18,814.3
Construction in Progress	-	-	787.5	1,572.5	1,695.9
Property/Plant/Equipment - Gross	-	-	20,328.5	26,818.3	25,096.0
Accumulated Depreciation	-	-	-14,351.9	-18,624.5	-17,178.2
Property/Plant/Equipment - Net	5,943.7	5,654.7	5,976.6	8,193.9	7,917.7
Goodwill, Net	-	-	3,842.2	4,568.2	4,448.2
Intangibles - Gross	-	-	3,195.6	3,513.7	-
Accumulated Intangible Amortization	-	-	-2,361.1	-2,414.7	-
Intangibles, Net	4,216.2	4,247.5	834.4	1,099.0	1,231.6
LT Investment - Affiliate Companies	1,483.0	1,372.1	754.0	898.2	839.6
LT Investments - Other	2,309.0	2,336.7	2,194.8	3,865.2	4,013.1
Long Term Investments	3,792.0	3,708.8	2,948.7	4,763.4	4,852.7
Note Receivable - Long Term	74.0	83.1	110.0	137.7	151.5
Deferred Income Tax - Long Term Asset	1,112.9	619.2	694.9	562.4	506.0
Other Long Term Assets, Total	1,112.9	619.2	694.9	562.4	506.0
Total Assets	22,688.3	21,995.9	27,559.5	27,126.8	27,960.9
Accounts Payable	1,448.6	1,409.8	1,459.6	1,958.4	2,033.6
Accrued Expenses	-	-	59.0	74.6	-
Notes Payable/Short Term Debt	0.0	0.0	104.6	0.0	0.0
Current Portion - Long Term Debt/Capital Leases	1,960.1	521.9	307.2	652.8	1,401.2
Customer Advances	-	-	47.0	152.1	-
Income Taxes Payable	294.7	456.9	462.8	360.1	273.8
Other Payables	359.5	368.7	-	-	-
Discontinued Operations - Current Liability	17.2	114.2	3,980.4	0.0	119.5
Other Current Liabilities	1,493.5	1,524.0	2,228.3	1,825.0	2,229.6
Other Current liabilities, Total	2,164.9	2,463.9	6,718.5	2,337.2	2,623.0
Total Current Liabilities	5,573.6	4,395.5	8,649.0	5,023.1	6,057.8
Long Term Debt	1,935.0	3,563.4	3,838.2	5,663.0	5,952.2
Capital Lease Obligations	-	-	8.0	133.4	155.7
Total Long Term Debt	1,935.0	3,563.4	3,846.2	5,796.4	6,107.9
Total Debt	3,895.1	4,085.3	4,258.1	6,449.2	7,509.1
Deferred Income Tax - LT Liability	545.9	624.4	673.5	898.2	955.0
Deferred Income Tax	545.9	624.4	673.5	898.2	955.0
Minority Interest	146.7	120.7	795.5	697.3	668.6
Reserves	1,056.0	1,316.3	1,282.5	1,565.3	1,479.0
Pension Benefits - Underfunded	5,789.1	3,641.3	4,398.9	5,708.9	5,494.9
Other Long Term Liabilities	560.4	569.9	701.6	654.2	700.6
Other Liabilities, Total	7,405.5	5,527.5	6,383.1	7,928.4	7,674.5
Total Liabilities	15,606.7	14,231.6	20,347.3	20,343.3	21,463.8
Common Stock	615.9	604.9	625.2	668.6	647.8
Common Stock	615.9	604.9	625.2	668.6	647.8
Retained Earnings (Accumulated Deficit)	6,465.8	7,159.3	6,587.0	6,114.9	5,849.3
Total Equity	7,081.7	7,764.2	7,212.2	6,783.5	6,497.1
Total Liabilities & Shareholders’ Equity	22,688.3	21,995.9	27,559.5	27,126.8	27,960.9
Shares Outstanding - Common Stock Primary Issue	466.0	466.0	466.0	466.0	466.0
Total Common Shares Outstanding	466.0	466.0	466.0	466.0	466.0
Treasury Shares - Common Stock Primary Issue	0.0	0.0	-	-	-
Employees	33,298	33,556	34,407	38,681	40,767
Accumulated Intangible Amort, Suppl.	-	-	2,361.1	2,414.7	2,143.5
Deferred Revenue - Current	-	-	47.0	152.1	-
Deferred Revenue - Long Term	-	-	0.0	4.3	-
Total Capital Leases, Supplemental	-	-	12.1	163.6	183.5
Capital Lease Payments Due in Year 1	-	-	2.7	30.1	27.8
Capital Lease Payments Due in Year 2	-	-	2.0	18.7	22.2
Capital Lease Payments Due in Year 3	-	-	2.0	18.7	22.2
Capital Lease Payments Due in Year 4	-	-	2.0	18.7	22.2
Capital Lease Payments Due in Year 5	-	-	2.0	18.7	22.2
Capital Lease Payments Due in 2-3 Years	-	-	4.0	37.3	44.5
Capital Lease Payments Due in 4-5 Years	-	-	4.0	37.3	44.5
Cap. Lease Pymts. Due in Year 6 & Beyond	-	-	1.3	58.8	66.7
Total Operating Leases, Supplemental	-	-	478.9	520.8	417.0
Operating Lease Payments Due in Year 1	-	-	83.2	91.8	61.2
Operating Lease Payments Due in Year 2	-	-	53.7	58.1	47.6
Operating Lease Payments Due in Year 3	-	-	53.7	58.1	47.6
Operating Lease Payments Due in Year 4	-	-	53.7	58.1	47.6
Operating Lease Payments Due in Year 5	-	-	53.7	58.1	47.6
Operating Lease Pymts. Due in 2-3 Years	-	-	107.3	116.2	95.2
Operating Lease Pymts. Due in 4-5 Years	-	-	107.3	116.2	95.2
Oper. Lse. Pymts. Due in Year 6 & Beyond	-	-	181.1	196.6	165.4
Pension Obligation - Domestic	-	-	9,361.3	4,678.7	4,102.0
Plan Assets - Domestic	-	-	4,763.8	4,535.2	4,045.0
Funded Status - Domestic	-	-	-4,597.5	-143.5	-57.0
Unfunded Plan Obligations	-	-	662.7	5,981.5	5,371.2
Total Funded Status	-	-	-5,260.2	-6,124.9	-5,428.1
Discount Rate - Domestic	-	-	5.00%	5.50%	6.00%
Discount Rate - Foreign	-	-	5.03%	5.54%	6.02%
Expected Rate of Return - Domestic	-	-	4.93%	5.00%	5.00%
Expected Rate of Return - Foreign	-	-	5.35%	5.35%	5.41%
Compensation Rate - Domestic	-	-	2.54%	2.53%	2.50%
Compensation Rate - Foreign	-	-	2.62%	2.63%	2.68%
Pension Payment Rate - Domestic	-	-	2.00%	2.00%	2.00%
Pension Payment Rate - Foreign	-	-	2.06%	2.07%	2.02%
Equity % - Domestic	-	-	9.90%	-	-
Debt Securities % - Domestic	-	-	79.70%	-	-
Real Estate % - Domestic	-	-	0.50%	-	-
Other Investments % - Domestic	-	-	9.90%	-	-
Total Plan Obligations	-	-	10,024.1	10,660.2	9,473.2
Total Plan Assets	-	-	4,763.8	4,535.2	4,045.0

Annual Cash Flows

Financials in: USD (mil)

Financial Glossary

	31-Dec-2012	31-Dec-2011	31-Dec-2010	31-Dec-2009	31-Dec-2008
Period Length	12 Months	12 Months	12 Months	12 Months	12 Months
UpdateType/Date	Updated Normal 31-Dec-2012	Restated Normal 31-Dec-2012	Updated Normal 31-Dec-2010	Reclassified Normal 31-Dec-2010	Reclassified Normal 31-Dec-2009
Filed Currency	EUR	EUR	EUR	EUR	EUR
Exchange Rate (Period Average)	0.778237	0.71919	0.755078	0.719047	0.683679
Auditor	PricewaterhouseCoopers AG	PricewaterhouseCoopers AG	PricewaterhouseCoopers AG	PricewaterhouseCoopers LLP	PricewaterhouseCoopers LLP
Auditor Opinion	Unqualified	Unqualified	Unqualified	Unqualified	Unqualified
Net Income/Starting Line	2,411.9	2,554.3	1,773.3	730.1	1,187.7
Depreciation	1,028.0	1,091.5	1,058.2	1,140.4	1,636.7
Depreciation/Depletion	1,028.0	1,091.5	1,058.2	1,140.4	1,636.7
Discontinued Operations	0.0	-175.2	667.5	977.7	10.2
Unusual Items	-5.1	7.0	-27.8	-20.9	-266.2
Other Non-Cash Items	-452.3	-383.8	86.1	-331.0	-226.7
Non-Cash Items	-457.4	-552.0	725.8	625.8	-482.7
Accounts Receivable	-41.1	-168.2	-327.1	93.2	-318.9
Inventories	-163.2	-354.6	-237.1	616.1	-634.8
Accounts Payable	-38.5	105.7	317.8	19.5	275.0
Other Assets & Liabilities, Net	-231.3	-150.2	-99.3	91.8	-416.9
Other Operating Cash Flow	-683.6	-706.4	-463.5	-407.5	-678.7
Changes in Working Capital	-1,157.7	-1,273.7	-809.2	413.0	-1,774.2
Cash from Operating Activities	1,824.6	1,820.1	2,748.1	2,909.4	567.5
Purchase of Fixed Assets	-1,311.9	-1,230.6	-1,018.4	-1,125.1	-1,704.0
Capital Expenditures	-1,311.9	-1,230.6	-1,018.4	-1,125.1	-1,704.0
Acquisition of Business	-56.5	-186.3	-72.8	-34.8	-122.9
Sale of Business	-	1,419.7	83.4	175.2	482.7
Sale of Fixed Assets	105.4	86.2	70.2	97.4	191.6
Other Investing Cash Flow	-819.8	-920.5	-746.9	8.3	340.8
Other Investing Cash Flow Items, Total	-771.0	399.1	-666.2	246.2	892.2
Cash from Investing Activities	-2,082.9	-831.5	-1,684.6	-878.9	-811.8
Other Financing Cash Flow	-14.1	-23.6	-31.8	-84.8	-51.2
Financing Cash Flow Items	-14.1	-23.6	-31.8	-84.8	-51.2
Cash Dividends Paid - Common	-546.1	-556.2	-423.8	-389.4	-504.6
Total Cash Dividends Paid	-546.1	-556.2	-423.8	-389.4	-504.6
Common Stock, Net	39.8	25.0	34.4	11.1	27.8
Issuance (Retirement) of Stock, Net	39.8	25.0	34.4	11.1	27.8
Total Debt Issued	268.6	367.1	470.1	1,705.0	1,437.8
Total Debt Reduction	-349.5	-696.6	-548.3	-2,789.8	-389.1
Issuance (Retirement) of Debt, Net	-81.0	-329.5	-78.1	-1,084.8	1,048.7
Cash from Financing Activities	-601.4	-884.3	-499.3	-1,547.9	520.7
Foreign Exchange Effects	-1.3	-20.9	53.0	-5.6	5.9
Net Change in Cash	-860.9	83.4	617.2	477.0	282.3
Net Cash - Beginning Balance	1,813.1	1,878.5	1,172.1	753.8	510.5
Net Cash - Ending Balance	952.2	1,961.9	1,789.2	1,230.8	792.8
Cash Interest Paid	208.2	269.7	263.5	-	326.2
Cash Taxes Paid	597.5	561.7	317.8	-	447.6

Annual Income Statement

Financials in: USD (mil)

Except for share items (millions) and per share items (actual units)

	31-Dec-2012	31-Dec-2011	31-Dec-2010	31-Dec-2009	31-Dec-2008
Period Length	12 Months	12 Months	12 Months	12 Months	12 Months
UpdateType/Date	Updated Normal 31-Dec-2012	Updated Normal 31-Dec-2011	Reclassified Normal 31-Dec-2011	Restated Normal 31-Dec-2010	Restated Normal 31-Dec-2009
Filed Currency	EUR	EUR	EUR	EUR	EUR
Exchange Rate (Period Average)	0.778237	0.71919	0.755078	0.719047	0.683679
Auditor	PricewaterhouseCoopers AG	PricewaterhouseCoopers AG	PricewaterhouseCoopers AG	PricewaterhouseCoopers LLP	PricewaterhouseCoopers LLP
Auditor Opinion	Unqualified	Unqualified	Unqualified	Unqualified	Unqualified
Revenues	17,512.7	20,217.2	17,614.1	14,627.7	23,217.0
Other Operating Income	-	1,400.2	1,267.4	1,182.1	1,508.0
Income from the Disposals of Assets	-	19.5	14.6	-	-
Total Revenue	17,512.7	21,636.9	18,896.1	15,809.8	24,725.0
As Reported Other Operating Expense	1,657.6	-	-	-	-
Income from the Disposals of Assets	-	-	-	-11.1	-285.2
Research & Development	505.0	507.5	447.6	414.4	454.9
Selling Expenses	1,595.9	1,726.9	1,586.6	1,408.8	1,774.2
General Administrative Expenses	831.4	921.9	802.6	721.8	1,082.4
Cost of Materials	12,464.1	14,248.0	12,502.0	10,750.3	18,113.8
Other Operating Income	-1,953.1	-	-	-	-
Reversal of Impairment	-	-	-	-	-29.3
Translation Result	-	324.0	324.5	-	-
Investment Result	-	513.1	597.3	-	-
Impairment Losses Pursuant to IAS 36	-	203.0	169.5	94.6	406.6
Impairment Losses Pursuant to IAS 39	-	23.6	21.2	27.8	46.8
Impairment losses Pursuant to IFRS 5	-	12.5	0.0	52.8	11.7
Expenses for Restructuring	-	11.1	41.1	82.1	92.1
Loss on Disposal of Assets	-	52.8	21.2	23.6	112.6
Other Operating Expenses	-	538.1	609.2	1,514.5	1,756.7
Total Operating Expense	15,100.8	19,082.6	17,122.7	15,079.7	23,537.4
Interest Income	45.0	69.5	30.5	44.5	111.2
Interest Expense	-503.7	-344.8	-323.1	-596.6	-886.4
Investments Recognized at Equity	111.8	111.2	71.5	79.3	93.6
Interest Expense/Pensions	-	-254.5	-274.1	-	-
Other Financial Result	6.4	9.7	13.2	5.6	23.4
Net Income Before Taxes	2,071.3	2,145.5	1,291.3	262.8	529.5
Provision for Income Taxes	591.1	627.1	231.8	75.1	187.2
Net Income After Taxes	1,480.3	1,518.4	1,059.5	187.7	342.3
Minority Interest	-3.9	-4.2	-78.1	-100.1	-102.4
Net Income Before Extra. Items	1,476.4	1,514.2	981.4	87.6	239.9
Discontinued Operations	19.3	-108.5	-9.3	246.2	171.1
Net Income	1,495.7	1,405.7	972.1	333.8	411.0
Income Available to Com Excl ExtraOrd	1,476.4	1,514.2	981.4	87.6	239.9
Income Available to Com Incl ExtraOrd	1,495.7	1,405.7	972.1	333.8	411.0
Basic Weighted Average Shares	466.0	466.0	464.6	466.0	466.0
Basic EPS Excluding ExtraOrdinary Items	3.17	3.25	2.11	0.19	0.51
Basic EPS Including ExtraOrdinary Items	3.21	3.02	2.09	0.72	0.88
Dilution Adjustment	-	-	-	0.0	-
Diluted Net Income	1,495.7	1,405.7	972.1	333.8	411.0
Diluted Weighted Average Shares	466.0	466.0	464.6	466.0	466.0
Diluted EPS Excluding ExtraOrd Items	3.17	3.25	2.11	0.19	0.51
Diluted EPS Including ExtraOrd Items	3.21	3.02	2.09	0.72	0.88
DPS-Ordinary Shares	-	1.27	1.14	0.96	0.00
Gross Dividends - Common Stock	-	590.9	529.7	-	0.0
Normalized Income Before Taxes	2,071.3	2,475.0	1,529.6	532.6	884.9
Inc Tax Ex Impact of Sp Items	591.1	723.4	274.6	152.2	312.9
Normalized Income After Taxes	1,480.3	1,751.6	1,255.1	380.5	572.0
Normalized Inc. Avail to Com.	1,476.4	1,747.4	1,177.0	280.3	469.6
Basic Normalized EPS	3.17	3.75	2.53	0.60	1.01
Diluted Normalized EPS	3.17	3.75	2.53	0.60	1.01
Depreciation of Tangibles	1,028.0	707.7	819.8	860.9	947.8
Amortization of Intangibles	-	130.7	151.0	187.7	220.9
Interest Expense	503.7	-	-	-	-
Interest Expense	-	344.8	323.1	596.6	886.4
Rental Expenses	-	129.3	123.2	-	-
Research & Development	505.0	507.5	447.6	414.4	454.9
Current Tax	-	545.1	529.7	-	188.7
Current Tax - Total	-	545.1	529.7	-	188.7
Deferred Tax	-	82.0	-298.0	-	-1.5
Deferred Tax - Total	-	82.0	-298.0	-	-1.5
Income Tax - Total	-	627.1	231.8	-	187.2
Current Service Cost	152.9	148.8	123.2	118.2	146.3
Interest Cost	463.9	504.7	495.3	521.5	555.8
Expected Return on Plan Assets	-253.1	-250.3	-221.2	-218.3	-241.3
Amortization	43.7	9.7	263.5	132.1	-121.4
Effect of Curtailments & Settlements	0.0	8.3	11.9	0.0	-1.5
Effect of Assets Ceiling	-15.4	16.7	-152.3	-101.5	171.1
Reclassification Pursuant to IFRS 5	-3.9	2.8	0.0	-	-
Domestic Pension Plan Expense	388.1	440.8	520.5	452.0	509.0
Defined Contribution Expenses - Germany	-	-	-	-	231.1
Defined Contribution Expenses - Foreign	-	-	-	-	13.2
Total Pension Expense	388.1	440.8	520.5	452.0	753.3
Discount Rate - Domestic	3.75%	4.75%	5.00%	5.50%	6.00%
Discount Rate - Foreign	3.78%	4.76%	5.03%	5.54%	6.02%
Compensation Rate - Domestic	2.50%	2.50%	2.54%	2.53%	2.53%
Compensation Rate - Foreign	2.58%	2.60%	2.62%	2.63%	2.68%
Pension Increase - Domestic	2.00%	2.00%	2.00%	2.00%	2.00%
Pension Increase - Foreign	1.99%	2.02%	2.06%	2.07%	2.02%
Expected Return on Plan Assets-Domestic	4.71%	4.80%	4.93%	5.00%	5.00%
Expected Return on Plan Assets - Foreign	4.86%	5.05%	5.35%	5.35%	5.41%

Annual Balance Sheet

Financials in: USD (mil)

	31-Dec-2012	31-Dec-2011	31-Dec-2010	31-Dec-2009	31-Dec-2008
UpdateType/Date	Reclassified Normal 30-Sep-2013	Reclassified Normal 31-Dec-2012	Updated Normal 31-Dec-2010	Updated Normal 31-Dec-2009	Restated Normal 31-Dec-2009
Filed Currency	EUR	EUR	EUR	EUR	EUR
Exchange Rate	0.7566	0.770327	0.745406	0.696986	0.719399
Auditor	PricewaterhouseCoopers AG	PricewaterhouseCoopers AG	PricewaterhouseCoopers AG	PricewaterhouseCoopers LLP	PricewaterhouseCoopers LLP
Auditor Opinion	Unqualified	Unqualified	Unqualified	Unqualified	Unqualified
Raw Materials	-	-	649.3	819.2	928.6
Work in Progress	-	-	140.9	210.9	208.5
Finished Goods	-	-	1,336.2	1,251.1	1,915.5
Total Inventory	2,270.7	2,135.5	-	-	-
Current Income Tax	159.9	77.9	63.1	228.1	180.7
Reported Net Trade/Accounts Receivable	2,229.7	2,221.1	-	-	-
Trade Receivables	-	-	-	3,081.8	3,575.2
Trade Receivables Net	-	-	2,459.1	-	-
Provisions for Doubtfull Accounts	-	-	-9.4	-	-
Other Receivables	429.6	464.7	257.6	375.9	554.6
Prepayments	-	-	56.3	61.7	-
Defferals/Accruals	-	-	30.9	73.2	-
Financial Current Assets	1,435.4	893.1	649.3	430.4	458.7
Liquid Capital	979.4	1,829.1	1,479.7	1,269.8	745.1
Assets Held for Sale	44.9	61.0	6,039.7	0.0	286.4
Total Current Assets	7,549.6	7,682.5	13,152.6	7,802.2	8,853.2
Intangibles Gross	-	-	3,195.6	3,513.7	-
Accumulated Amortization	-	-	-2,361.1	-2,414.7	-
Intangible Assets	4,216.2	4,247.5	-	-	1,231.6
Goodwill, Net	-	-	3,842.2	4,568.2	4,448.2
Land, Landrights & Buildings	-	-	3,910.6	4,817.9	4,585.8
Plant & Machinery	-	-	14,288.8	18,859.8	17,332.5
Other Plant, Office Furniture& Equipment	-	-	1,341.6	1,568.2	1,481.8
Advance Payments & Constr. in Progress	-	-	787.5	1,572.5	1,695.9
Depreciation	-	-	-14,351.9	-18,624.5	-17,178.2
Investment Property	2,048.6	2,005.6	2,049.9	2,229.6	2,087.9
Investments Recognized at Equity	1,483.0	1,372.1	754.0	898.2	839.6
Financial Assets	260.4	331.0	144.9	1,635.6	1,925.2
Deferred Tax	1,112.9	619.2	694.9	562.4	506.0
Other Income Tax Assets	27.8	29.9	30.9	57.4	50.0
Other Receivables	46.3	53.2	79.2	80.3	101.5
Property/Plant/Equipment	5,943.7	5,654.7	-	-	-
Total Assets	22,688.3	21,995.9	27,559.5	27,126.8	27,960.9
Other Provisions	1,493.5	1,524.0	1,968.1	1,522.3	1,768.1
Income Tax Liabilities	294.7	456.9	462.8	360.1	273.8
Current Portion of LT Debt	-	-	303.2	622.7	1,373.4
Current Portion of LT Leasing	-	-	4.0	30.1	27.8
Financial Liabilities	1,960.1	521.9	-	-	-
ST Debt	-	-	104.6	-	-
Trade Payables	1,448.6	1,409.8	1,459.6	1,958.4	2,033.6
Prepayments	-	-	47.0	152.1	-
Deffrerals/Accruals	-	-	59.0	74.6	-
Other Liabilities	-	-	260.3	302.7	461.5
Liab. Assoc. with Assets Held for Sale	17.2	114.2	3,980.4	0.0	119.5
Other Payables	359.5	368.7	-	-	-
Total Current Liabilities	5,573.6	4,395.5	8,649.0	5,023.1	6,057.8
Long-Term Debt	1,935.0	3,563.4	3,838.2	5,663.0	5,952.2
Long-Term Financial Leasing	-	-	8.0	133.4	155.7
Total Long Term Debt	1,935.0	3,563.4	3,846.2	5,796.4	6,107.9
Provisions for Pensions & Other Benefits	5,789.1	3,641.3	4,398.9	5,708.9	5,494.9
Other Provisions	1,056.0	1,316.3	1,282.5	1,565.3	1,479.0
Deferred Tax Liabilities	545.9	624.4	673.5	898.2	955.0
Other Income Tax Liabilies	152.0	90.9	93.9	87.5	166.8
Financial Liabilities	-	-	64.4	-	-
Other Liabilitiess	408.4	479.0	543.3	566.7	533.8
Minority Interest	146.7	120.7	795.5	697.3	668.6
Total Liabilities	15,606.7	14,231.6	20,347.3	20,343.3	21,463.8
Capital Issued	615.9	604.9	625.2	668.6	647.8
Reserves	6,465.8	7,159.3	-	-	-
Capital Reserve	-	-	1,562.9	1,671.5	1,619.4
Accumulated Income/Loss	-	-	5,296.4	5,057.5	4,951.4
Accumulated Other Comprehensive Income	-	-	-272.3	-614.1	-721.4
Total Equity	7,081.7	7,764.2	7,212.2	6,783.5	6,497.1
Total Liabilities & Shareholders' Equity	22,688.3	21,995.9	27,559.5	27,126.8	27,960.9
S/O-Ordinary Shares	466.0	466.0	466.0	466.0	466.0
Total Common Shares Outstanding	466.0	466.0	466.0	466.0	466.0
T/S-Ordinary Shares	0.0	0.0	-	-	-
Deferred Income - Current	-	-	47.0	152.1	-
Deferred Income - Long-Term	-	-	0.0	4.3	-
Accumulated Amortization of Intangibles	-	-	2,361.1	2,414.7	2,143.5
Employees	33,298	33,556	34,407	38,681	40,767
Capital Lease Maturing Within 1 Year	-	-	2.7	30.1	27.8
Capital Lease Maturing in 1 - 5 Years	-	-	8.0	74.6	89.0
Capital Lease Payment - Remaining Part	-	-	1.3	58.8	66.7
Total Capital Leases, Supplemental	-	-	12.1	163.6	183.5
Operating Lease Maturing Within 1 Year	-	-	83.2	91.8	61.2
Operating Lease Maturing in 1 - 5 Years	-	-	214.6	232.4	190.4
Operating Lease Payment - Remaining Part	-	-	181.1	196.6	165.4
Total Operating Leases, Supplemental	-	-	478.9	520.8	417.0
Unfunded Plan Obligations	-	-	662.7	5,981.5	5,371.2
Present Value of Defined Benefit Oblig.	-	-	9,361.3	4,678.7	4,102.0
Fair Value of Plan Assets	-	-	4,763.8	4,535.2	4,045.0
Funded Status	-	-	-4,597.5	-143.5	-57.0
Total Funded Status	-	-	-5,260.2	-6,124.9	-5,428.1
Discount Rate - Domestic	-	-	5.00%	5.50%	6.00%
Discount Rate - Foreign	-	-	5.03%	5.54%	6.02%
Compensation Rate - Domestic	-	-	2.54%	2.53%	2.50%
Compensation Rate - Foreign	-	-	2.62%	2.63%	2.68%
Pension Increase - Domestic	-	-	2.00%	2.00%	2.00%
Pension Increase - Foreign	-	-	2.06%	2.07%	2.02%
Expected Return on Plan Assets-Domestic	-	-	4.93%	5.00%	5.00%
Expected Return on Plan Assets - Foreign	-	-	5.35%	5.35%	5.41%
Shares	-	-	9.90%	-	-
Debt Securities % - Domestic	-	-	79.70%	-	-
Real Estate % - Domestic	-	-	0.50%	-	-
Other Investments % - Domestic	-	-	9.90%	-	-

Annual Cash Flows

Financials in: USD (mil)

	31-Dec-2012	31-Dec-2011	31-Dec-2010	31-Dec-2009	31-Dec-2008
Period Length	12 Months	12 Months	12 Months	12 Months	12 Months
UpdateType/Date	Updated Normal 31-Dec-2012	Restated Normal 31-Dec-2012	Updated Normal 31-Dec-2010	Reclassified Normal 31-Dec-2010	Reclassified Normal 31-Dec-2009
Filed Currency	EUR	EUR	EUR	EUR	EUR
Exchange Rate (Period Average)	0.778237	0.71919	0.755078	0.719047	0.683679
Auditor	PricewaterhouseCoopers AG	PricewaterhouseCoopers AG	PricewaterhouseCoopers AG	PricewaterhouseCoopers LLP	PricewaterhouseCoopers LLP
Auditor Opinion	Unqualified	Unqualified	Unqualified	Unqualified	Unqualified
EBIT - Coninuing Operations	2,411.9	2,554.3	1,773.3	730.1	1,187.7
Depreciation	1,028.0	1,091.5	1,058.2	1,140.4	1,636.7
Disposal of Non-Current Assets	-5.1	7.0	-27.8	-20.9	-266.2
Other Non-Cash Income/Expense	-	-	-	-	49.7
Change in Inventories	-163.2	-354.6	-237.1	616.1	-634.8
Change in Receivables/Other Assets	-41.1	-168.2	-327.1	93.2	-318.9
Change in Payables/Advance Payments	-38.5	105.7	317.8	19.5	275.0
Change in Provisions	-245.4	-278.1	-233.1	-274.0	-270.6
Change in Other Provisions	-206.9	-105.7	319.2	-57.0	-5.9
Change in Assets/Liabilities	-231.3	-150.2	-99.3	91.8	-416.9
Interest Paid	-208.2	-269.7	-263.5	-308.7	-326.2
Interest Received	37.3	44.5	45.0	118.2	33.6
Dividends Received	84.8	80.6	72.8	69.5	61.4
Income Taxes Paid	-597.5	-561.7	-317.8	-286.5	-447.6
Cashflow from Discontinued Operations	0.0	-175.2	667.5	977.7	10.2
Cash from Operating Activities	1,824.6	1,820.1	2,748.1	2,909.4	567.5
Purchase of Tangib./Intangib./Inv.Prop.	-1,311.9	-1,230.6	-1,018.4	-1,125.1	-1,704.0
Sale of Tangib./Intangib./Inv. Property	105.4	86.2	70.2	97.4	191.6
Acquisition/Sale of Business, Net	-15.4	-	-	-	-
Acqisition of Business/Equity Investment	-41.1	-186.3	-72.8	-34.8	-122.9
Acquisition/Sale of Business, Net	-	1,419.7	83.4	175.2	482.7
Change in Current Securities & Deposits	-	-	-482.1	8.3	340.8
Cash inflows/outflows relating to securi	-305.8	-364.3	-	-	-
Contribution to Pension Taxes	-514.0	-556.2	-264.9	0.0	-
Cash from Investing Activities	-2,082.9	-831.5	-1,684.6	-878.9	-811.8
Change in Minority Interests	0.0	-4.2	0.0	-	-
Capital Contributions	39.8	25.0	34.4	11.1	27.8
Payments to Minority Interest	-14.1	-19.5	-31.8	-84.8	-51.2
Results from Prev. Year & Dividends Paid	-546.1	-556.2	-423.8	-389.4	-504.6
Addition of Financial Liabilities	268.6	367.1	470.1	1,705.0	1,437.8
Repayment of Financial Liabilities	-349.5	-696.6	-548.3	-2,789.8	-389.1
Cash from Financing Activities	-601.4	-884.3	-499.3	-1,547.9	520.7
Foreign Exchange Effects	-1.3	-20.9	53.0	-5.6	5.9
Net Change in Cash	-860.9	83.4	617.2	477.0	282.3
Cash Balance at Beginning of the Year	1,813.1	1,878.5	1,172.1	753.8	510.5
Cash Balance at the End of the Year	952.2	1,961.9	1,789.2	1,230.8	792.8
Cash Interest Paid	208.2	269.7	263.5	-	326.2
Cash Taxes Paid	597.5	561.7	317.8	-	447.6

Financial Health

Financials in: USD (mil)

Except for share items (millions) and per share items (actual units)

Key Indicators USD (mil)

Â	Quarter Ending 30-Sep-2013	Quarter Ending Yr Ago	Annual Year End 31-Dec-2012	1 Year Growth	3 Year Growth	5 Year Growth
Total Revenue1 (?)	4,287.2	-3.57%	17,512.7	-12.42%	6.23%	-2.31%
Research & Development1 (?)	132.4	6.38%	505.0	7.67%	9.66%	-
Operating Income1 (?)	169.4	-78.52%	2,411.9	2.18%	52.91%	14.76%
Income Available to Common Excl Extraord Items1 (?)	197.2	-56.30%	1,476.4	5.51%	163.22%	33.20%
Basic EPS Excl Extraord Items1 (?)	0.42	-56.31%	3.17	5.51%	163.22%	33.20%
Capital Expenditures2 (?)	990.2	26.60%	1,311.9	15.37%	8.07%	-0.90%
Cash from Operating Activities2 (?)	1,182.4	-9.57%	1,824.6	8.48%	-12.12%	3.17%
Free Cash Flow (?)	197.4	-63.41%	527.4	-5.90%	-32.25%	22.10%
Total Assets3 (?)	23,272.9	-0.43%	22,688.3	1.31%	-3.17%	-2.83%
Total Liabilities3 (?)	14,168.5	-2.97%	15,606.7	7.71%	-5.92%	-4.95%
Total Long Term Debt3 (?)	1,870.1	-46.71%	1,935.0	-46.67%	-28.71%	-17.16%
Employees3 (?)	-	-	33298	-0.77%	-4.87%	-5.01%
Total Common Shares Outstanding3 (?)	466.0	0.00%	466.0	0.00%	0.00%	0.00%
1-ExchangeRate: EUR to USD Average for Period	0.755500	Â	0.778237	Â	Â	Â
2-ExchangeRate: EUR to USD Average for Period	0.759463	Â	0.778237	Â	Â	Â
3-ExchangeRate: EUR to USD Period End Date	0.739530	Â	0.756600	Â	Â	Â

Key Ratios

Â	31-Dec-2012	31-Dec-2011	31-Dec-2010	31-Dec-2009	31-Dec-2008
Profitability
Gross Margin (?)	28.83%	34.09%	33.79%	32.00%	26.74%
Operating Margin (?)	13.77%	11.81%	9.38%	4.62%	4.80%
Pretax Margin (?)	11.83%	9.92%	6.83%	1.66%	2.14%
Net Profit Margin (?)	8.43%	7.00%	5.19%	0.55%	0.97%
Financial Strength
Current Ratio (?)	1.35	1.75	1.52	1.55	1.46
Long Term Debt/Equity (?)	0.27	0.46	0.53	0.85	0.94
Total Debt/Equity (?)	0.55	0.53	0.59	0.95	1.16
Management Effectiveness
Return on Assets (?)	6.75%	5.83%	4.06%	0.69%	1.17%
Return on Equity (?)	20.27%	19.18%	14.67%	1.34%	3.54%
Efficiency
Receivables Turnover (?)	6.40	7.42	6.16	4.01	5.71
Inventory Turnover (?)	5.77	6.34	5.95	4.08	6.19
Asset Turnover (?)	0.80	0.83	0.72	0.58	0.85

Market Valuation USD (mil)

P/E (TTM) (?)	14.90	.	Enterprise Value2 (?)	16,550.9
Price/Sales (TTM) (?)	0.99	.	Enterprise Value/Revenue (TTM) (?)	0.94
Price/Book (MRQ) (?)	1.91	.	Enterprise Value/EBITDA (TTM) (?)	5.79
Market Cap as of 22-Nov-20131 (?)	17,340.4	.
1-ExchangeRate: EUR to USD on 22-Nov-2013	0.742250
2-ExchangeRate: EUR to USD on 30-Sep-2013	0.739530

Annual Ratios

Financials in: USD (mil)

Except for share items (millions) and per share items (actual units)

	31-Dec-2012	31-Dec-2011	31-Dec-2010	31-Dec-2009	31-Dec-2008
Financial Strength
Current Ratio (?)	1.35	1.75	1.52	1.55	1.46
Quick/Acid Test Ratio (?)	0.94	1.25	0.57	1.07	0.91
Working Capital1 (?)	1,975.9	3,286.9	4,503.6	2,779.1	2,795.4
Long Term Debt/Equity (?)	0.27	0.46	0.53	0.85	0.94
Total Debt/Equity (?)	0.55	0.53	0.59	0.95	1.16
Long Term Debt/Total Capital (?)	0.18	0.30	0.34	0.44	0.44
Total Debt/Total Capital (?)	0.35	0.34	0.37	0.49	0.54
Payout Ratio (?)	-	38.94%	53.92%	510.36%	0.00%
Effective Tax Rate (?)	28.54%	29.23%	17.95%	28.57%	35.36%
Total Capital1 (?)	10,976.7	11,849.5	11,470.3	13,232.7	14,006.1
Efficiency
Asset Turnover (?)	0.80	0.83	0.72	0.58	0.85
Inventory Turnover (?)	5.77	6.34	5.95	4.08	6.19
Days In Inventory (?)	63.27	57.53	61.38	89.38	58.98
Receivables Turnover (?)	6.40	7.42	6.16	4.01	5.71
Days Receivables Outstanding (?)	57.07	49.19	59.27	91.03	63.95
Revenue/Employee2 (?)	540,978	601,994	556,318	421,660	576,383
Operating Income/Employee2 (?)	74,504	71,066	52,208	19,473	27,687
EBITDA/Employee2 (?)	106,259	94,394	80,789	47,440	54,931
Profitability
Gross Margin (?)	28.83%	34.09%	33.79%	32.00%	26.74%
Operating Margin (?)	13.77%	11.81%	9.38%	4.62%	4.80%
EBITDA Margin (?)	19.64%	15.68%	14.52%	11.25%	9.53%
EBIT Margin (?)	13.77%	11.81%	9.38%	4.62%	4.80%
Pretax Margin (?)	11.83%	9.92%	6.83%	1.66%	2.14%
Net Profit Margin (?)	8.43%	7.00%	5.19%	0.55%	0.97%
R&D Expense/Revenue (?)	2.88%	2.35%	2.37%	2.62%	1.84%
COGS/Revenue (?)	71.17%	65.85%	66.16%	68.00%	73.26%
SG&A Expense/Revenue (?)	13.86%	14.73%	15.87%	23.06%	18.66%
Management Effectiveness
Return on Assets (?)	6.75%	5.83%	4.06%	0.69%	1.17%
Return on Equity (?)	20.27%	19.18%	14.67%	1.34%	3.54%
Valuation
Free Cash Flow/Share2 (?)	1.13	1.18	3.76	3.95	-2.32
Operating Cash Flow/Share 2 (?)	4.03	3.65	5.97	6.44	1.16
1-ExchangeRate: EUR to USD Period End Date	0.7566	0.770327	0.745406	0.696986	0.719399
2-ExchangeRate: EUR to USD Average for Period	0.7566	0.770327	0.745406	0.696986	0.719399

Current Market Multiples

Market Cap/Earnings (TTM) (?)	14.90
Market Cap/Equity (MRQ) (?)	1.91
Market Cap/Revenue (TTM) (?)	0.99
Market Cap/EBIT (TTM) (?)	8.69
Market Cap/EBITDA (TTM) (?)	6.09
Enterprise Value/Earnings (TTM) (?)	14.17
Enterprise Value/Equity (MRQ) (?)	1.82
Enterprise Value/Revenue (TTM) (?)	0.94
Enterprise Value/EBIT (TTM) (?)	8.26
Enterprise Value/EBITDA (TTM) (?)	5.79

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	Rs.61.96
UK Pound	1	Rs.101.14
Euro	1	Rs.85.33

INFORMATION DETAILS

Report Prepared by :

NNA

RATING EXPLANATIONS

RATING		STATUS	PROPOSED CREDIT LINE
>86	Aaa	Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums	Unlimited
71-85	Aa	Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums	Large
56-70	A	Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums	Fairly Large
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory
26-40	B	Capability to overcome financial difficulties seems comparatively below average.	Small
11-25	Ca	Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity	Limited with full security
<10	C	Absolute credit risk exists. Caution needed to be exercised	Credit not recommended
----	NB	New Business	----

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

Financial condition (40%) Ownership background (20%) Payment record (10%)

Credit history (10%) Market trend (10%) Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.